<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Med</journal-id><journal-id journal-id-type="pmc-domain-id">216</journal-id><journal-id journal-id-type="pmc-domain">bmcmedicine</journal-id><journal-title-group><journal-title>BMC Medicine</journal-title></journal-title-group><issn pub-type="epub">1741-7015</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11887073</article-id><article-id pub-id-type="pmcid-ver">PMC11887073.1</article-id><article-id pub-id-type="pmcaid">11887073</article-id><article-id pub-id-type="pmcaiid">11887073</article-id><article-id pub-id-type="pmid">40055683</article-id><article-id pub-id-type="doi">10.1186/s12916-025-03952-z</article-id><article-id pub-id-type="publisher-id">3952</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Psychiatric and neuropsychiatric sequelae of COVID-19 within 2&#160;years: a multinational cohort study</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Chai</surname><given-names initials="Y">Yi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Lam</surname><given-names initials="ICH">Ivan C. H.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Man</surname><given-names initials="KKC">Kenneth K. C.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hayes</surname><given-names initials="JF">Joseph F.</given-names></name><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wan</surname><given-names initials="EYF">Eric Y. F.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="X">Xue</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chui</surname><given-names initials="CSL">Celine S. L.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lau</surname><given-names initials="WCY">Wallis C. Y.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lin</surname><given-names initials="X">Xiaoyu</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yin</surname><given-names initials="C">Can</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fan</surname><given-names initials="M">Min</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chan</surname><given-names initials="EW">Esther W.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wong</surname><given-names initials="ICK">Ian C. K.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Luo</surname><given-names initials="H">Hao</given-names></name><address><email>hao.luo1@uwaterloo.ca</email></address><xref ref-type="aff" rid="Aff15">15</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01vy4gh70</institution-id><institution-id institution-id-type="GRID">grid.263488.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 0472 9649</institution-id><institution>School of Public Health, </institution><institution>Shenzhen University Medical School, Shenzhen University, </institution></institution-wrap>Shenzhen, Guangdong China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02zhqgq86</institution-id><institution-id institution-id-type="GRID">grid.194645.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2174 2757</institution-id><institution>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, </institution><institution>The University of Hong Kong, </institution></institution-wrap>Hong Kong SAR, China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02zhqgq86</institution-id><institution-id institution-id-type="GRID">grid.194645.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2174 2757</institution-id><institution>The Hong Kong Jockey Club Centre for Suicide Research and Prevention, The University of Hong Kong, </institution></institution-wrap>Hong Kong SAR, China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02jx3x895</institution-id><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2190 1201</institution-id><institution>Research Department of Practice and Policy, School of Pharmacy, </institution><institution>University College London, </institution></institution-wrap>London, UK </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02mbz1h25</institution-id><institution-id institution-id-type="ISNI">0000 0005 0817 5873</institution-id><institution>Laboratory of Data Discovery for Health (D24h), </institution></institution-wrap>Hong Kong Science Park, Hong Kong SAR, China </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02jx3x895</institution-id><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2190 1201</institution-id><institution>Division of Psychiatry, </institution><institution>University College London, </institution></institution-wrap>London, UK </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03ekq2173</institution-id><institution-id institution-id-type="GRID">grid.450564.6</institution-id><institution>Camden and Islington NHS Foundation Trust, </institution></institution-wrap>London, UK </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02zhqgq86</institution-id><institution-id institution-id-type="GRID">grid.194645.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2174 2757</institution-id><institution>Department of Family Medicine and Primary Care, LKS Faculty of Medicine, </institution><institution>The University of Hong Kong, </institution></institution-wrap>Hong Kong SAR, China </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02zhqgq86</institution-id><institution-id institution-id-type="GRID">grid.194645.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2174 2757</institution-id><institution>Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, </institution><institution>The University of Hong Kong, </institution></institution-wrap>Hong Kong SAR, China </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02zhqgq86</institution-id><institution-id institution-id-type="GRID">grid.194645.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2174 2757</institution-id><institution>School of Nursing, LKS Faculty of Medicine, </institution><institution>The University of Hong Kong, </institution></institution-wrap>Hong Kong SAR, China </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02zhqgq86</institution-id><institution-id institution-id-type="GRID">grid.194645.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2174 2757</institution-id><institution>School of Public Health, LKS Faculty of Medicine, </institution><institution>The University of Hong Kong, </institution></institution-wrap>Hong Kong SAR, China </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01mk44223</institution-id><institution-id institution-id-type="GRID">grid.418848.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0458 4007</institution-id><institution>Real-World Solutions, IQVIA, </institution></institution-wrap>Durham, NC USA </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02zhqgq86</institution-id><institution-id institution-id-type="GRID">grid.194645.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2174 2757</institution-id><institution>The University of Hong Kong Shenzhen Institute of Research and Innovation, </institution></institution-wrap>Shenzhen, Guangdong China </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05j0ve876</institution-id><institution-id institution-id-type="GRID">grid.7273.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0376 4727</institution-id><institution>Aston Pharmacy School, </institution><institution>Aston University, </institution></institution-wrap>Birmingham, UK </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01aff2v68</institution-id><institution-id institution-id-type="GRID">grid.46078.3d</institution-id><institution-id institution-id-type="ISNI">0000 0000 8644 1405</institution-id><institution>School of Public Health Sciences, </institution><institution>University of Waterloo, </institution></institution-wrap>Waterloo, ON Canada </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>23</volume><issue-id pub-id-type="pmc-issue-id">478654</issue-id><elocation-id>144</elocation-id><history><date date-type="received"><day>5</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>14</day><month>2</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>03</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>07</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-10 10:25:44.460"><day>10</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12916_2025_Article_3952.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">The long-term psychiatric and neuropsychiatric sequelae of COVID-19 across diverse populations remain not fully understood. This cohort study aims to investigate the short-, medium-, and long-term risks of psychiatric and neuropsychiatric disorders following COVID-19 infection in five countries.</p></sec><sec><title>Methods</title><p id="Par2">This population-based multinational network study used electronic medical records from France, Italy, Germany, and the UK and claims data from the USA. The initial target and comparator cohorts were identified using an exact matching approach based on age and sex. Individuals diagnosed with COVID-19 or those with a positive SARS-CoV-2 screening test between December 1, 2019, and December 1, 2020, were included as targets. Up to ten comparators without COVID-19 for each target were selected using the propensity score matching approach. All individuals were followed from the index date until the end of continuous enrolment or the last healthcare encounter. Cox proportional hazard regression models were fitted to estimate the risk of incident diagnosis of depression, anxiety disorders, alcohol misuse or dependence, substance misuse or dependence, bipolar disorders, psychoses, personality disorders, self-harm and suicide, sleep disorders, dementia, and neurodevelopmental disorders within the first 6&#160;months (short-term), 6&#160;months to 1&#160;year (medium-term), and 1 to 2&#160;years (long-term) post-infection.</p></sec><sec><title>Results</title><p id="Par3">A total of 303,251 individuals&#160;with COVID-19 and 22,108,925 individuals without COVID-19 from five countries were originally included. Within the first 6&#160;months, individuals with COVID-19 had a significantly higher risk of any studied disorders in all databases, with Hazard Ratios (HRs) ranging from 1.14 (95% CI, 1.07&#8211;1.22) in Germany to 1.89 (1.64&#8211;2.17) in Italy. Increased risks were consistently observed for depression, anxiety disorders, and sleep disorders across almost all countries. During the medium- and long-term periods, higher risks were observed only for depression (medium-term: 1.29, 1.18&#8211;1.41; long-term: 1.36, 1.25&#8211;1.47), anxiety disorders (medium-term: 1.29, 1.20&#8211;1.38; long-term: 1.37, 1.29&#8211;1.47), and sleep disorders (medium-term: 1.10, 1.01&#8211;1.21; long-term: 1.14, 1.05&#8211;1.24) in France, and dementia (medium-term: 1.65, 1.28&#8211;2.10) in the UK.</p></sec><sec><title>Conclusions</title><p id="Par4">Our study suggests that increased risks of psychiatric and neuropsychiatric outcomes were consistently observed only within, and not after, the 6-month observation period across all databases, except for certain conditions in specific countries.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12916-025-03952-z.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Long COVID</kwd><kwd>SARS-CoV-2</kwd><kwd>Psychiatric disorders</kwd><kwd>Neuropsychiatric disorders</kwd><kwd>Mental health</kwd><kwd>OMOP CDM</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001839</institution-id><institution>University Grants Committee</institution></institution-wrap></funding-source><award-id>C7154-20GF</award-id><principal-award-recipient><name name-style="western"><surname>Wong</surname><given-names>Ian C. K.</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par14">The COVID-19 pandemic has had unprecedented impacts on global health. In addition to its physical health consequences, concerns have been raised regarding the potential psychiatric and neuropsychiatric complications following infection [<xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR5">5</xref>]. Studies have indicated that SARS-CoV-2 can directly invade the central nervous system or trigger an immune response that leads to inflammation and subsequent psychiatric and neuropsychiatric manifestations [<xref ref-type="bibr" rid="CR6">6</xref>&#8211;<xref ref-type="bibr" rid="CR9">9</xref>]. Furthermore, psychosocial stressors associated with the pandemic, such as social isolation, financial insecurity, and fear of illness, may contribute to a higher incidence of psychiatric symptoms [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par15">Several studies have examined the association between COVID-19 infection and psychiatric and neuropsychiatric disorders [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR15">15</xref>]. Three USA-based studies using population-based electronic medical records found that COVID-19 infection was associated with an increased risk of psychiatric and neuropsychiatric diagnoses within 6&#160;months post-infection, highlighting a particular vulnerability to mood disorders, anxiety disorders, psychotic disorders, substance use disorders, insomnia, and dementia among individuals with COVID-19 [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. A recent study included over 400,000 individuals from the UK Biobank database between March 1, 2020, and September 30, 2021, and found that individuals with COVID-19 were more likely to receive subsequent diagnoses of psychotic, mood, anxiety, alcohol use, and sleep disorders than their COVID-19-free counterparts during the 1-year follow-up period [<xref ref-type="bibr" rid="CR14">14</xref>]. Furthermore, a binational study indicated that during a follow-up period of up to 28&#160;months, COVID-19 infection was associated with a higher risk of psychiatric disorders, including anxiety disorders and post-traumatic stress disorders, in the UK and Hong Kong [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par16">While these studies provide valuable insights into the psychiatric and neuropsychiatric sequelae of COVID-19, most have limited follow-up periods, leaving knowledge gaps regarding the post-acute sequelae of SARS-CoV-2. Additionally, the generalizability of findings from specific countries, predominantly the USA and the UK, to other regions is uncertain due to varying healthcare systems and public health responses to the pandemic. Therefore, findings generated from multiple populations and diverse healthcare systems, with large sample sizes, extended follow-up periods, standardized study designs, and a broader range of psychiatric and neuropsychiatric outcomes, are essential to enhance the current understanding of the psychiatric and neuropsychiatric sequelae of COVID-19 [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par17">This population-based multinational network study aims to comprehensively investigate the short-, medium-, and long-term psychiatric and neuropsychiatric sequelae of COVID-19 using electronic medical records and claims data from over 25 million individuals across five countries. This investigation sheds light on the potential psychiatric and neurological effects of COVID-19 at various stages, thereby informing the development of effective prevention and management strategies for affected individuals.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Data sources</title><p id="Par18">We used data from five databases. These comprised four electronic medical record databases, the IQVIA Longitudinal Patient Database France (France IQVIA), IQVIA Disease Analyser Germany (Germany IQVIA), Longitudinal Patient Database Italy (Italy IQVIA), and IQVIA Medical Research Data UK (UK IMRD). The fifth database was the IQVIA PharMetrics Plus in the USA (US PharMetrics Plus), a claims-based database. All data were routinely collected and converted to the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM), version 5, maintained by the Observational Health Data Sciences and Informatics (OHDSI) network [<xref ref-type="bibr" rid="CR18">18</xref>]. The standardized structure and content of these databases allow data partners to execute common analytical syntax locally and contribute aggregated results without sharing individual-level data. The databases used in this study are all population-based databases covering patients with diverse socioeconomic characteristics. These databases have been extensively used in previous studies to assess the physical and psychological consequences of the COVID-19 pandemic [<xref ref-type="bibr" rid="CR19">19</xref>&#8211;<xref ref-type="bibr" rid="CR21">21</xref>]. Detailed descriptions of these databases, including their representativeness and comparability, are presented in Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1 and have been previously reported [<xref ref-type="bibr" rid="CR20">20</xref>&#8211;<xref ref-type="bibr" rid="CR22">22</xref>].</p></sec><sec id="Sec4"><title>Study design and participants</title><p id="Par19">This study used data between December 1, 2018, and December 1, 2022. We identified target and comparator cohorts using an exact matching approach based on age and sex. The target cohort consisted of all individuals who received a diagnosis of COVID-19 or a positive SARS-CoV-2 screening test result between December 1, 2019, and December 1, 2020. Targets with any negative SARS-CoV-2 screening test results within 3&#160;days of the index date were excluded to eliminate potential false positives. The diagnostic codes for identifying individuals with COVID-19 were determined through internal and external consultations with epidemiologists, clinicians, and data scientists, and the list was further adjusted during the preliminary testing process. Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2 shows the final list of diagnostic codes. The initial comparator cohort included individuals without any diagnosis or positive test results for COVID-19 between December 1, 2019, and December 1, 2022. The earliest date of COVID-19 confirmation was designated as the index date for the targets, and the same dates were assigned as the index date for their corresponding matched comparators.</p><p id="Par20">Individuals were eligible for the study if they had continuous observation for at least 365&#160;days prior to the index date and at least 1&#160;day after the index date. A maximum of ten comparators for each target were selected using the propensity score matching approach, although some targets may have fewer than ten comparator candidates. The standardized difference of mean&#160;was used to assess the covariate balance between target and comparator cohorts, with a threshold of 0.2 [<xref ref-type="bibr" rid="CR23">23</xref>]. The propensity scores were calculated based on a wide range of predefined generic characteristics, including demographics, diagnoses, drug exposures, measurement, medical procedures, and health service use behaviors observed 365&#160;days prior to and on the index date [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. A large-scale regularized regression was employed for covariate selection and propensity score calculation, which has been widely used in previous research for confounding adjustment [<xref ref-type="bibr" rid="CR25">25</xref>&#8211;<xref ref-type="bibr" rid="CR28">28</xref>]. All individuals were followed from the index date until the end of continuous enrolment (for UK IMRD and US PharMetrics Plus) or the last healthcare encounter (for France IQVIA, Germany IQVIA, and Italy IQVIA). Our preliminary analysis identified 805,065 targets and 39,754,216 comparators in the US PharMetrics Plus database. Due to computational limitations, we used a stratified random sampling approach to select 20% of individuals from the target and comparator cohorts within each age and sex stratum for the US PharMetrics Plus database.</p></sec><sec id="Sec5"><title>Outcomes</title><p id="Par21">The study outcomes included depression, anxiety disorders, alcohol misuse or dependence, substance misuse or dependence, bipolar disorders, psychoses, personality disorders, self-harm and suicide, sleep disorders, dementia, and neurodevelopmental disorders. The corresponding diagnostic codes are shown in Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S3. Only the first diagnosis of each outcome following the index date was used. We also estimated the risk of any of the 11 outcomes to assess the overall psychiatric and neuropsychiatric sequelae of COVID-19.</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par22">The short-, medium-, and long-term periods were defined as 6&#160;months, 6&#160;months to 1&#160;year, and 1 to 2&#160;years since the index date, respectively. For the analysis of each outcome, individuals were excluded if they had the outcome of interest within 365&#160;days prior to the start of the short- (the index date), medium-, and long-term observation to ensure the identification of incident cases. We used the term &#8220;incident&#8221; broadly to represent a first-ever diagnosis and a potentially prevalent diagnosis that became active after at least 365&#160;days. The exclusion was performed before the propensity score matching step. We tabulated baseline characteristics to evaluate covariate balance before and after propensity score adjustment and report the incidence of outcomes by disease and database. Cox proportional hazards regression models were fitted to quantify the short-, medium-, and long-term associations between each outcome of interest and COVID-19 infection. All parameters are expressed as hazard ratios (HRs) with 95% confidence intervals (95% CIs). Two-sided <italic toggle="yes">P</italic> values of 0.05 or below were considered indicative of statistical significance. We further stratified the analyses by sex and age group (i.e.,&#8201;&lt;&#8201;18, 18&#8211;24, 25&#8211;44, 45&#8211;64, and 65&#8201;+&#8201;years) to examine potential differences in associations related to sex and age [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>].</p><p id="Par23">All analyses were conducted using statistical software R (version 4.2.0) [<xref ref-type="bibr" rid="CR31">31</xref>]. The analysis packages were built on the open-source OHDSI <italic toggle="yes">CohortMethod</italic> and <italic toggle="yes">Cyclops</italic> R packages [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. The study protocol and all statistical analysis packages were prespecified before the analysis. The data are reported following the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline [<xref ref-type="bibr" rid="CR34">34</xref>].</p></sec><sec id="Sec7"><title>Role of the funding source</title><p id="Par24">The funders of this study had no role in the study design, data collection, data analysis, interpretation, or writing of the report.</p></sec></sec><sec id="Sec8"><title>Results</title><p id="Par25">We initially identified 303,251 individuals with COVID-19 and 22,108,925 individuals without COVID-19 across five countries during the study period. Figure S1 in Supplement shows the study cohort selection procedure. After applying inclusion and exclusion criteria and conducting propensity score matching, the sample size varied by follow-up period, outcome, and database (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). In the target cohorts,&#160;the majority of individuals included for the 6-month risk analysis were females and aged 45&#8211;64&#160;years across all databases. The proportion of females ranged from 56.65% (<italic toggle="yes">N</italic>&#8201;=&#8201;30,181) for substance misuse or dependence&#160;in France to 45.76% (1382) for personality disorders in the Germnay. The proportion of individuals aged 45&#8211;64&#160;years ranged from 41.11% (3423) for personality disorders in Italy to 31.33% (11,131) for sleep disorders in the UK.
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Sample size, age and sex distribution, follow-up time, the number of psychiatric and neuropsychiatric events, and incidence rate in the short-term observation period by outcome and database</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Outcome</th><th align="left" rowspan="2" colspan="1">Database</th><th align="left" rowspan="2" colspan="1">Targets/comparators</th><th align="left" rowspan="2" colspan="1">No. of individuals after propensity score matching</th><th align="left" colspan="2" rowspan="1">Sex, <italic toggle="yes">N</italic> (%)</th><th align="left" colspan="5" rowspan="1">Age, <italic toggle="yes">N</italic> (%)</th><th align="left" rowspan="2" colspan="1">No. of follow-up years</th><th align="left" rowspan="2" colspan="1">No. of events</th><th align="left" rowspan="2" colspan="1">Incidence rate per 1000 person years</th></tr><tr><th align="left" colspan="1" rowspan="1"><bold>Males</bold></th><th align="left" colspan="1" rowspan="1"><bold>Females</bold></th><th align="left" colspan="1" rowspan="1"><bold>&#8201;&lt;&#8201;18&#160;years</bold></th><th align="left" colspan="1" rowspan="1"><bold>18&#8211;24&#160;years</bold></th><th align="left" colspan="1" rowspan="1"><bold>25&#8211;44&#160;years</bold></th><th align="left" colspan="1" rowspan="1"><bold>45&#8211;64&#160;years</bold></th><th align="left" colspan="1" rowspan="1"><bold>65&#8201;+&#8201;years</bold></th></tr></thead><tbody><tr><td align="left" rowspan="10" colspan="1"><bold>Depression</bold></td><td align="left" rowspan="2" colspan="1">France IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">343,950</td><td align="left" colspan="1" rowspan="1">151,145 (43.94)</td><td align="left" colspan="1" rowspan="1">189,065 (54.97)</td><td align="left" colspan="1" rowspan="1">33,331 (9.69)</td><td align="left" colspan="1" rowspan="1">30,319 (8.81)</td><td align="left" colspan="1" rowspan="1">101,733 (29.58)</td><td align="left" colspan="1" rowspan="1">114,444 (33.27)</td><td align="left" colspan="1" rowspan="1">54,955 (15.98)</td><td align="left" colspan="1" rowspan="1">150,206</td><td align="left" colspan="1" rowspan="1">4163</td><td align="left" colspan="1" rowspan="1">27.72</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">50,196</td><td align="left" colspan="1" rowspan="1">21,669 (43.17)</td><td align="left" colspan="1" rowspan="1">27,861 (55.50)</td><td align="left" colspan="1" rowspan="1">4486 (8.94)</td><td align="left" colspan="1" rowspan="1">4149 (8.27)</td><td align="left" colspan="1" rowspan="1">15,028 (29.94)</td><td align="left" colspan="1" rowspan="1">16,932 (33.73)</td><td align="left" colspan="1" rowspan="1">6861 (13.67)</td><td align="left" colspan="1" rowspan="1">22,669</td><td align="left" colspan="1" rowspan="1">1045</td><td align="left" colspan="1" rowspan="1">46.1</td></tr><tr><td align="left" rowspan="2" colspan="1">Germany IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">124,315</td><td align="left" colspan="1" rowspan="1">56,551 (45.49)</td><td align="left" colspan="1" rowspan="1">65,494 (52.68)</td><td align="left" colspan="1" rowspan="1">13,664 (10.99)</td><td align="left" colspan="1" rowspan="1">11,294 (9.08)</td><td align="left" colspan="1" rowspan="1">33,791 (27.18)</td><td align="left" colspan="1" rowspan="1">38,624 (31.07)</td><td align="left" colspan="1" rowspan="1">20,252 (16.29)</td><td align="left" colspan="1" rowspan="1">54,703</td><td align="left" colspan="1" rowspan="1">3079</td><td align="left" colspan="1" rowspan="1">56.29</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">18,044</td><td align="left" colspan="1" rowspan="1">8409 (46.60)</td><td align="left" colspan="1" rowspan="1">9566 (53.01)</td><td align="left" colspan="1" rowspan="1">1677 (9.29)</td><td align="left" colspan="1" rowspan="1">1710 (9.48)</td><td align="left" colspan="1" rowspan="1">5454 (30.23)</td><td align="left" colspan="1" rowspan="1">6257 (34.68)</td><td align="left" colspan="1" rowspan="1">2664 (14.76)</td><td align="left" colspan="1" rowspan="1">5296</td><td align="left" colspan="1" rowspan="1">626</td><td align="left" colspan="1" rowspan="1">75.46</td></tr><tr><td align="left" rowspan="2" colspan="1">Italy IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">45,797</td><td align="left" colspan="1" rowspan="1">18,003 (39.31)</td><td align="left" colspan="1" rowspan="1">23,567 (51.46)</td><td align="left" colspan="1" rowspan="1">1068 (2.33)</td><td align="left" colspan="1" rowspan="1">2913 (6.36)</td><td align="left" colspan="1" rowspan="1">11,710 (25.57)</td><td align="left" colspan="1" rowspan="1">18,413 (40.21)</td><td align="left" colspan="1" rowspan="1">11,610 (25.35)</td><td align="left" colspan="1" rowspan="1">20,704</td><td align="left" colspan="1" rowspan="1">470</td><td align="left" colspan="1" rowspan="1">22.7</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">7837</td><td align="left" colspan="1" rowspan="1">3067 (39.13)</td><td align="left" colspan="1" rowspan="1">3930 (50.15)</td><td align="left" colspan="1" rowspan="1">396 (5.05)</td><td align="left" colspan="1" rowspan="1">484 (6.18)</td><td align="left" colspan="1" rowspan="1">1968 (25.11)</td><td align="left" colspan="1" rowspan="1">3198 (40.81)</td><td align="left" colspan="1" rowspan="1">1767 (22.55)</td><td align="left" colspan="1" rowspan="1">3468</td><td align="left" colspan="1" rowspan="1">161</td><td align="left" colspan="1" rowspan="1">46.41</td></tr><tr><td align="left" rowspan="2" colspan="1">UK IMRD</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">306,950</td><td align="left" colspan="1" rowspan="1">132,653 (43.22)</td><td align="left" colspan="1" rowspan="1">172,172 (56.09)</td><td align="left" colspan="1" rowspan="1">35,363 (11.52)</td><td align="left" colspan="1" rowspan="1">30,667 (9.99)</td><td align="left" colspan="1" rowspan="1">95,572 (31.14)</td><td align="left" colspan="1" rowspan="1">95,302 (31.05)</td><td align="left" colspan="1" rowspan="1">42,316 (13.79)</td><td align="left" colspan="1" rowspan="1">135,034</td><td align="left" colspan="1" rowspan="1">1551</td><td align="left" colspan="1" rowspan="1">11.49</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">35,262</td><td align="left" colspan="1" rowspan="1">15,344 (43.51)</td><td align="left" colspan="1" rowspan="1">19,890 (56.41)</td><td align="left" colspan="1" rowspan="1">3838 (10.88)</td><td align="left" colspan="1" rowspan="1">3611 (10.24)</td><td align="left" colspan="1" rowspan="1">10,912 (30.95)</td><td align="left" colspan="1" rowspan="1">11,094 (31.46)</td><td align="left" colspan="1" rowspan="1">5697 (16.16)</td><td align="left" colspan="1" rowspan="1">16,111</td><td align="left" colspan="1" rowspan="1">210</td><td align="left" colspan="1" rowspan="1">13.03</td></tr><tr><td align="left" rowspan="2" colspan="1">US PharMetrics Plus</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">587,963</td><td align="left" colspan="1" rowspan="1">280,670 (47.74)</td><td align="left" colspan="1" rowspan="1">301,241 (51.23)</td><td align="left" colspan="1" rowspan="1">65,337 (11.11)</td><td align="left" colspan="1" rowspan="1">72,829 (12.39)</td><td align="left" colspan="1" rowspan="1">188,202 (32.01)</td><td align="left" colspan="1" rowspan="1">204,110 (34.71)</td><td align="left" colspan="1" rowspan="1">38,619 (6.57)</td><td align="left" colspan="1" rowspan="1">250,800</td><td align="left" colspan="1" rowspan="1">15,763</td><td align="left" colspan="1" rowspan="1">62.85</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">125,275</td><td align="left" colspan="1" rowspan="1">60,265 (48.11)</td><td align="left" colspan="1" rowspan="1">63,438 (50.64)</td><td align="left" colspan="1" rowspan="1">10,660 (8.51)</td><td align="left" colspan="1" rowspan="1">16,420 (13.11)</td><td align="left" colspan="1" rowspan="1">40,655 (32.45)</td><td align="left" colspan="1" rowspan="1">44,965 (35.89)</td><td align="left" colspan="1" rowspan="1">7311 (5.84)</td><td align="left" colspan="1" rowspan="1">56,516</td><td align="left" colspan="1" rowspan="1">3989</td><td align="left" colspan="1" rowspan="1">70.58</td></tr><tr><td align="left" rowspan="10" colspan="1"><bold>Anxiety disorders</bold></td><td align="left" rowspan="2" colspan="1">France IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">337,181</td><td align="left" colspan="1" rowspan="1">148,415 (44.02)</td><td align="left" colspan="1" rowspan="1">185,012 (54.87)</td><td align="left" colspan="1" rowspan="1">32,970 (9.78)</td><td align="left" colspan="1" rowspan="1">29,404 (8.72)</td><td align="left" colspan="1" rowspan="1">98,591 (29.24)</td><td align="left" colspan="1" rowspan="1">112,670 (33.42)</td><td align="left" colspan="1" rowspan="1">54,495 (16.16)</td><td align="left" colspan="1" rowspan="1">146,417</td><td align="left" colspan="1" rowspan="1">7262</td><td align="left" colspan="1" rowspan="1">49.6</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">49,004</td><td align="left" colspan="1" rowspan="1">21,210 (43.28)</td><td align="left" colspan="1" rowspan="1">27,133 (55.37)</td><td align="left" colspan="1" rowspan="1">4417 (9.01)</td><td align="left" colspan="1" rowspan="1">4008 (8.18)</td><td align="left" colspan="1" rowspan="1">14,488 (29.56)</td><td align="left" colspan="1" rowspan="1">16,636 (33.95)</td><td align="left" colspan="1" rowspan="1">6780 (13.84)</td><td align="left" colspan="1" rowspan="1">21,836</td><td align="left" colspan="1" rowspan="1">1867</td><td align="left" colspan="1" rowspan="1">85.5</td></tr><tr><td align="left" rowspan="2" colspan="1">Germany IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">125,945</td><td align="left" colspan="1" rowspan="1">57,116 (45.35)</td><td align="left" colspan="1" rowspan="1">66,615 (52.89)</td><td align="left" colspan="1" rowspan="1">13,547 (10.76)</td><td align="left" colspan="1" rowspan="1">11,229 (8.92)</td><td align="left" colspan="1" rowspan="1">33,711 (26.77)</td><td align="left" colspan="1" rowspan="1">39,261 (31.17)</td><td align="left" colspan="1" rowspan="1">21,481 (17.06)</td><td align="left" colspan="1" rowspan="1">55,556</td><td align="left" colspan="1" rowspan="1">2816</td><td align="left" colspan="1" rowspan="1">50.69</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">18,481</td><td align="left" colspan="1" rowspan="1">8554 (38.22)</td><td align="left" colspan="1" rowspan="1">9845 (53.27)</td><td align="left" colspan="1" rowspan="1">1673 (9.05)</td><td align="left" colspan="1" rowspan="1">1713 (9.27)</td><td align="left" colspan="1" rowspan="1">5507 (29.80)</td><td align="left" colspan="1" rowspan="1">6395 (34.60)</td><td align="left" colspan="1" rowspan="1">2825 (15.29)</td><td align="left" colspan="1" rowspan="1">8546</td><td align="left" colspan="1" rowspan="1">476</td><td align="left" colspan="1" rowspan="1">55.7</td></tr><tr><td align="left" rowspan="2" colspan="1">Italy IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">48,516</td><td align="left" colspan="1" rowspan="1">18,543 (38.22)</td><td align="left" colspan="1" rowspan="1">25,568 (52.70)</td><td align="left" colspan="1" rowspan="1">1067 (2.20)</td><td align="left" colspan="1" rowspan="1">2920 (6.02)</td><td align="left" colspan="1" rowspan="1">11,984 (24.70)</td><td align="left" colspan="1" rowspan="1">19,433 (40.05)</td><td align="left" colspan="1" rowspan="1">12,954 (26.70)</td><td align="left" colspan="1" rowspan="1">22,046</td><td align="left" colspan="1" rowspan="1">102</td><td align="left" colspan="1" rowspan="1">4.63</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">8334</td><td align="left" colspan="1" rowspan="1">3172 (38.06)</td><td align="left" colspan="1" rowspan="1">4281 (51.37)</td><td align="left" colspan="1" rowspan="1">376 (4.51)</td><td align="left" colspan="1" rowspan="1">484 (5.81)</td><td align="left" colspan="1" rowspan="1">2017 (24.20)</td><td align="left" colspan="1" rowspan="1">3394 (40.72)</td><td align="left" colspan="1" rowspan="1">1988 (23.85)</td><td align="left" colspan="1" rowspan="1">3733</td><td align="left" colspan="1" rowspan="1">41</td><td align="left" colspan="1" rowspan="1">10.98</td></tr><tr><td align="left" rowspan="2" colspan="1">UK IMRD</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">306,496</td><td align="left" colspan="1" rowspan="1">132,735 (43.31)</td><td align="left" colspan="1" rowspan="1">171,684 (56.02)</td><td align="left" colspan="1" rowspan="1">35,264 (11.51)</td><td align="left" colspan="1" rowspan="1">30,653 (10.00)</td><td align="left" colspan="1" rowspan="1">95,138 (31.04)</td><td align="left" colspan="1" rowspan="1">95,298 (31.09)</td><td align="left" colspan="1" rowspan="1">42,379 (13.83)</td><td align="left" colspan="1" rowspan="1">134,750</td><td align="left" colspan="1" rowspan="1">1656</td><td align="left" colspan="1" rowspan="1">12.29</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">35,204</td><td align="left" colspan="1" rowspan="1">15,354 (43.61)</td><td align="left" colspan="1" rowspan="1">19,823 (56.31)</td><td align="left" colspan="1" rowspan="1">3828 (10.87)</td><td align="left" colspan="1" rowspan="1">3603 (10.23)</td><td align="left" colspan="1" rowspan="1">10,859 (30.85)</td><td align="left" colspan="1" rowspan="1">11,093 (31.51)</td><td align="left" colspan="1" rowspan="1">5714 (16.23)</td><td align="left" colspan="1" rowspan="1">16,068</td><td align="left" colspan="1" rowspan="1">265</td><td align="left" colspan="1" rowspan="1">16.49</td></tr><tr><td align="left" rowspan="2" colspan="1">US PharMetrics Plus</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">550,374</td><td align="left" colspan="1" rowspan="1">267,744 (48.65)</td><td align="left" colspan="1" rowspan="1">277,405 (50.40)</td><td align="left" colspan="1" rowspan="1">62,654 (11.38)</td><td align="left" colspan="1" rowspan="1">67,134 (12.20)</td><td align="left" colspan="1" rowspan="1">171,792 (31.21)</td><td align="left" colspan="1" rowspan="1">193,141 (35.09)</td><td align="left" colspan="1" rowspan="1">38,181 (6.94)</td><td align="left" colspan="1" rowspan="1">232,441</td><td align="left" colspan="1" rowspan="1">23,985</td><td align="left" colspan="1" rowspan="1">103.19</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">117,948</td><td align="left" colspan="1" rowspan="1">57,768 (42.78)</td><td align="left" colspan="1" rowspan="1">58,625 (49.70)</td><td align="left" colspan="1" rowspan="1">10,270 (8.71)</td><td align="left" colspan="1" rowspan="1">15,263 (12.94)</td><td align="left" colspan="1" rowspan="1">37,434 (31.74)</td><td align="left" colspan="1" rowspan="1">42,648 (36.16)</td><td align="left" colspan="1" rowspan="1">7294 (6.18)</td><td align="left" colspan="1" rowspan="1">52,256</td><td align="left" colspan="1" rowspan="1">6802</td><td align="left" colspan="1" rowspan="1">130.16</td></tr><tr><td align="left" rowspan="10" colspan="1"><bold>Alcohol misuse or dependence</bold></td><td align="left" rowspan="2" colspan="1">France IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">367,132</td><td align="left" colspan="1" rowspan="1">157,063 (42.03)</td><td align="left" colspan="1" rowspan="1">205,589 (56.00)</td><td align="left" colspan="1" rowspan="1">33,453 (9.11)</td><td align="left" colspan="1" rowspan="1">30,960 (8.43)</td><td align="left" colspan="1" rowspan="1">107,526 (29.29)</td><td align="left" colspan="1" rowspan="1">124,545 (33.92)</td><td align="left" colspan="1" rowspan="1">60,126 (16.38)</td><td align="left" colspan="1" rowspan="1">161,455</td><td align="left" colspan="1" rowspan="1">285</td><td align="left" colspan="1" rowspan="1">1.77</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">53,556</td><td align="left" colspan="1" rowspan="1">22,508 (42.03)</td><td align="left" colspan="1" rowspan="1">30,321 (56.62)</td><td align="left" colspan="1" rowspan="1">4498 (8.40)</td><td align="left" colspan="1" rowspan="1">4230 (7.90)</td><td align="left" colspan="1" rowspan="1">15,924 (29.73)</td><td align="left" colspan="1" rowspan="1">18,501 (35.55)</td><td align="left" colspan="1" rowspan="1">7518 (14.04)</td><td align="left" colspan="1" rowspan="1">24,518</td><td align="left" colspan="1" rowspan="1">48</td><td align="left" colspan="1" rowspan="1">1.96</td></tr><tr><td align="left" rowspan="2" colspan="1">Germany IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">132,126</td><td align="left" colspan="1" rowspan="1">59,061 (44.70)</td><td align="left" colspan="1" rowspan="1">70,785 (53.57)</td><td align="left" colspan="1" rowspan="1">13,779 (10.43)</td><td align="left" colspan="1" rowspan="1">11,743 (8.89)</td><td align="left" colspan="1" rowspan="1">35,608 (26.95)</td><td align="left" colspan="1" rowspan="1">41,467 (31.38)</td><td align="left" colspan="1" rowspan="1">22,292 (16.87)</td><td align="left" colspan="1" rowspan="1">59,066</td><td align="left" colspan="1" rowspan="1">225</td><td align="left" colspan="1" rowspan="1">3.81</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">19,320</td><td align="left" colspan="1" rowspan="1">8832 (45.71)</td><td align="left" colspan="1" rowspan="1">10,401 (53.84)</td><td align="left" colspan="1" rowspan="1">1699 (8.79)</td><td align="left" colspan="1" rowspan="1">1788 (9.25)</td><td align="left" colspan="1" rowspan="1">5807 (30.06)</td><td align="left" colspan="1" rowspan="1">6729 (34.83)</td><td align="left" colspan="1" rowspan="1">2931 (15.17)</td><td align="left" colspan="1" rowspan="1">9082</td><td align="left" colspan="1" rowspan="1">18</td><td align="left" colspan="1" rowspan="1">1.98</td></tr><tr><td align="left" rowspan="2" colspan="1">Italy IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">49,053</td><td align="left" colspan="1" rowspan="1">18,715 (38.15)</td><td align="left" colspan="1" rowspan="1">25,913 (52.83)</td><td align="left" colspan="1" rowspan="1">1135 (2.31)</td><td align="left" colspan="1" rowspan="1">2953 (6.02)</td><td align="left" colspan="1" rowspan="1">12,135 (24.74)</td><td align="left" colspan="1" rowspan="1">19,696 (40.15)</td><td align="left" colspan="1" rowspan="1">13,019 (26.54)</td><td align="left" colspan="1" rowspan="1">22,310</td><td align="left" colspan="1" rowspan="1">25</td><td align="left" colspan="1" rowspan="1">1.12</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">8429</td><td align="left" colspan="1" rowspan="1">3196 (37.92)</td><td align="left" colspan="1" rowspan="1">4341 (51.50)</td><td align="left" colspan="1" rowspan="1">378 (4.48)</td><td align="left" colspan="1" rowspan="1">489 (5.80)</td><td align="left" colspan="1" rowspan="1">2042 (24.23)</td><td align="left" colspan="1" rowspan="1">3438 (40.79)</td><td align="left" colspan="1" rowspan="1">1998 (23.70)</td><td align="left" colspan="1" rowspan="1">3787</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">2.11</td></tr><tr><td align="left" rowspan="2" colspan="1">UK IMRD</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">311,033</td><td align="left" colspan="1" rowspan="1">133,857 (43.04)</td><td align="left" colspan="1" rowspan="1">175,097 (56.30)</td><td align="left" colspan="1" rowspan="1">35,421 (11.39)</td><td align="left" colspan="1" rowspan="1">31,407 (10.10)</td><td align="left" colspan="1" rowspan="1">97,301 (31.28)</td><td align="left" colspan="1" rowspan="1">96,272 (30.95)</td><td align="left" colspan="1" rowspan="1">42,713 (13.73)</td><td align="left" colspan="1" rowspan="1">137,067</td><td align="left" colspan="1" rowspan="1">166</td><td align="left" colspan="1" rowspan="1">1.21</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">35,731</td><td align="left" colspan="1" rowspan="1">15,482 (43.33)</td><td align="left" colspan="1" rowspan="1">20,222 (56.60)</td><td align="left" colspan="1" rowspan="1">3844 (10.76)</td><td align="left" colspan="1" rowspan="1">3698 (10.35)</td><td align="left" colspan="1" rowspan="1">11,112 (31.10)</td><td align="left" colspan="1" rowspan="1">11,204 (31.36)</td><td align="left" colspan="1" rowspan="1">5761 (16.12)</td><td align="left" colspan="1" rowspan="1">16,369</td><td align="left" colspan="1" rowspan="1">18</td><td align="left" colspan="1" rowspan="1">1.1</td></tr><tr><td align="left" rowspan="2" colspan="1">US PharMetrics Plus</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">650,750</td><td align="left" colspan="1" rowspan="1">296,118 (45.50)</td><td align="left" colspan="1" rowspan="1">347,827 (53.45)</td><td align="left" colspan="1" rowspan="1">68,346 (10.50)</td><td align="left" colspan="1" rowspan="1">31,025 (4.77)</td><td align="left" colspan="1" rowspan="1">208,601 (32.06)</td><td align="left" colspan="1" rowspan="1">225,803 (34.70)</td><td align="left" colspan="1" rowspan="1">45,719 (7.03)</td><td align="left" colspan="1" rowspan="1">280,702</td><td align="left" colspan="1" rowspan="1">2187</td><td align="left" colspan="1" rowspan="1">7.79</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">138,027</td><td align="left" colspan="1" rowspan="1">63,304 (45.86)</td><td align="left" colspan="1" rowspan="1">72,995 (52.88)</td><td align="left" colspan="1" rowspan="1">11,182 (8.10)</td><td align="left" colspan="1" rowspan="1">18,050 (13.08)</td><td align="left" colspan="1" rowspan="1">44,764 (32.43)</td><td align="left" colspan="1" rowspan="1">49,472 (35.84)</td><td align="left" colspan="1" rowspan="1">8803 (6.38)</td><td align="left" colspan="1" rowspan="1">63,223</td><td align="left" colspan="1" rowspan="1">510</td><td align="left" colspan="1" rowspan="1">8.07</td></tr><tr><td align="left" rowspan="10" colspan="1"><bold>Substance misuse or dependence</bold></td><td align="left" rowspan="2" colspan="1">France IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">365,179</td><td align="left" colspan="1" rowspan="1">155,996 (42.72)</td><td align="left" colspan="1" rowspan="1">204,721 (56.06)</td><td align="left" colspan="1" rowspan="1">33,438 (9.16)</td><td align="left" colspan="1" rowspan="1">30,851 (8.45)</td><td align="left" colspan="1" rowspan="1">106,844 (29.26)</td><td align="left" colspan="1" rowspan="1">123,677 (33.87)</td><td align="left" colspan="1" rowspan="1">59,884 (16.40)</td><td align="left" colspan="1" rowspan="1">160,454</td><td align="left" colspan="1" rowspan="1">790</td><td align="left" colspan="1" rowspan="1">4.92</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">53,277</td><td align="left" colspan="1" rowspan="1">22,352 (41.95)</td><td align="left" colspan="1" rowspan="1">30,181 (56.65)</td><td align="left" colspan="1" rowspan="1">4496 (8.44)</td><td align="left" colspan="1" rowspan="1">4220 (7.92)</td><td align="left" colspan="1" rowspan="1">15,813 (29.68)</td><td align="left" colspan="1" rowspan="1">18,364 (34.47)</td><td align="left" colspan="1" rowspan="1">7491 (14.06)</td><td align="left" colspan="1" rowspan="1">24,363</td><td align="left" colspan="1" rowspan="1">137</td><td align="left" colspan="1" rowspan="1">5.62</td></tr><tr><td align="left" rowspan="2" colspan="1">Germany IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">130,475</td><td align="left" colspan="1" rowspan="1">58,150 (44.57)</td><td align="left" colspan="1" rowspan="1">70,055 (53.69)</td><td align="left" colspan="1" rowspan="1">13,767 (10.55)</td><td align="left" colspan="1" rowspan="1">11,659 (8.94)</td><td align="left" colspan="1" rowspan="1">35,071 (26.88)</td><td align="left" colspan="1" rowspan="1">40,856 (31.31)</td><td align="left" colspan="1" rowspan="1">22,049 (16.90)</td><td align="left" colspan="1" rowspan="1">58,168</td><td align="left" colspan="1" rowspan="1">789</td><td align="left" colspan="1" rowspan="1">13.56</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">19,146</td><td align="left" colspan="1" rowspan="1">8730 (45.60)</td><td align="left" colspan="1" rowspan="1">10,327 (53.94)</td><td align="left" colspan="1" rowspan="1">1698 (8.87)</td><td align="left" colspan="1" rowspan="1">1779 (9.29)</td><td align="left" colspan="1" rowspan="1">5741 (29.99)</td><td align="left" colspan="1" rowspan="1">6660 (34.78)</td><td align="left" colspan="1" rowspan="1">2901 (15.15)</td><td align="left" colspan="1" rowspan="1">8978</td><td align="left" colspan="1" rowspan="1">96</td><td align="left" colspan="1" rowspan="1">10.69</td></tr><tr><td align="left" rowspan="2" colspan="1">Italy IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">48,940</td><td align="left" colspan="1" rowspan="1">18,651 (37.71)</td><td align="left" colspan="1" rowspan="1">25,879 (52.88)</td><td align="left" colspan="1" rowspan="1">1089 (2.23)</td><td align="left" colspan="1" rowspan="1">2952 (6.03)</td><td align="left" colspan="1" rowspan="1">12,112 (24.75)</td><td align="left" colspan="1" rowspan="1">19,672 (40.20)</td><td align="left" colspan="1" rowspan="1">12,962 (26.49)</td><td align="left" colspan="1" rowspan="1">22,248</td><td align="left" colspan="1" rowspan="1">58</td><td align="left" colspan="1" rowspan="1">2.61</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">8410</td><td align="left" colspan="1" rowspan="1">3188 (37.91)</td><td align="left" colspan="1" rowspan="1">4333 (51.52)</td><td align="left" colspan="1" rowspan="1">387 (4.60)</td><td align="left" colspan="1" rowspan="1">488 (5.80)</td><td align="left" colspan="1" rowspan="1">2039 (24.24)</td><td align="left" colspan="1" rowspan="1">3434 (40.83)</td><td align="left" colspan="1" rowspan="1">1990 (23.66)</td><td align="left" colspan="1" rowspan="1">3778</td><td align="left" colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">3.44</td></tr><tr><td align="left" rowspan="2" colspan="1">UK IMRD</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">310,792</td><td align="left" colspan="1" rowspan="1">133,683 (43.01)</td><td align="left" colspan="1" rowspan="1">175,049 (56.32)</td><td align="left" colspan="1" rowspan="1">35,410 (11.39)</td><td align="left" colspan="1" rowspan="1">31,356 (10.90)</td><td align="left" colspan="1" rowspan="1">97,241 (31.29)</td><td align="left" colspan="1" rowspan="1">96,226 (30.96)</td><td align="left" colspan="1" rowspan="1">42,678 (13.73)</td><td align="left" colspan="1" rowspan="1">13,6943</td><td align="left" colspan="1" rowspan="1">271</td><td align="left" colspan="1" rowspan="1">1.98</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">35,708</td><td align="left" colspan="1" rowspan="1">15,462 (45.28)</td><td align="left" colspan="1" rowspan="1">20,219 (56.62)</td><td align="left" colspan="1" rowspan="1">3843 (10.76)</td><td align="left" colspan="1" rowspan="1">3693 (10.34)</td><td align="left" colspan="1" rowspan="1">11,105 (31.10)</td><td align="left" colspan="1" rowspan="1">11,200 (31.37)</td><td align="left" colspan="1" rowspan="1">5755 (16.12)</td><td align="left" colspan="1" rowspan="1">16,356</td><td align="left" colspan="1" rowspan="1">27</td><td align="left" colspan="1" rowspan="1">1.65</td></tr><tr><td align="left" rowspan="2" colspan="1">US PharMetrics Plus</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">621,083</td><td align="left" colspan="1" rowspan="1">281,202 (45.28)</td><td align="left" colspan="1" rowspan="1">333,365 (53.67)</td><td align="left" colspan="1" rowspan="1">67,865 (10.93)</td><td align="left" colspan="1" rowspan="1">78,144 (12.58)</td><td align="left" colspan="1" rowspan="1">198,313 (31.93)</td><td align="left" colspan="1" rowspan="1">213,416 (34.36)</td><td align="left" colspan="1" rowspan="1">43,549 (7.01)</td><td align="left" colspan="1" rowspan="1">266,538</td><td align="left" colspan="1" rowspan="1">9895</td><td align="left" colspan="1" rowspan="1">37.12</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">132,328</td><td align="left" colspan="1" rowspan="1">60,379 (45.63)</td><td align="left" colspan="1" rowspan="1">70,237 (53.08)</td><td align="left" colspan="1" rowspan="1">11,107 (8.39)</td><td align="left" colspan="1" rowspan="1">17,435 (13.18)</td><td align="left" colspan="1" rowspan="1">42,736 (32.30)</td><td align="left" colspan="1" rowspan="1">46,994 (35.51)</td><td align="left" colspan="1" rowspan="1">8369 (6.32)</td><td align="left" colspan="1" rowspan="1">59,960</td><td align="left" colspan="1" rowspan="1">2653</td><td align="left" colspan="1" rowspan="1">44.25</td></tr><tr><td align="left" rowspan="10" colspan="1"><bold>Bipolar disorders</bold></td><td align="left" rowspan="2" colspan="1">France IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">367,324</td><td align="left" colspan="1" rowspan="1">157,450 (45.78)</td><td align="left" colspan="1" rowspan="1">205,425 (59.73)</td><td align="left" colspan="1" rowspan="1">33,444 (9.72)</td><td align="left" colspan="1" rowspan="1">30,951 (9.00)</td><td align="left" colspan="1" rowspan="1">107,537 (31.27)</td><td align="left" colspan="1" rowspan="1">124,762 (36.27)</td><td align="left" colspan="1" rowspan="1">60,126 (17.48)</td><td align="left" colspan="1" rowspan="1">161,580</td><td align="left" colspan="1" rowspan="1">113</td><td align="left" colspan="1" rowspan="1">0.7</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">53,580</td><td align="left" colspan="1" rowspan="1">22,553 (42.09)</td><td align="left" colspan="1" rowspan="1">30,299 (56.55)</td><td align="left" colspan="1" rowspan="1">4497 (8.39)</td><td align="left" colspan="1" rowspan="1">4231 (7.90)</td><td align="left" colspan="1" rowspan="1">15,927 (29.73)</td><td align="left" colspan="1" rowspan="1">18,527 (34.58)</td><td align="left" colspan="1" rowspan="1">7518 (14.03)</td><td align="left" colspan="1" rowspan="1">24,538</td><td align="left" colspan="1" rowspan="1">17</td><td align="left" colspan="1" rowspan="1">0.69</td></tr><tr><td align="left" rowspan="2" colspan="1">Germany IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">132,427</td><td align="left" colspan="1" rowspan="1">59,271 (44.76)</td><td align="left" colspan="1" rowspan="1">70,871 (53.52)</td><td align="left" colspan="1" rowspan="1">13,782 (10.41)</td><td align="left" colspan="1" rowspan="1">11,736 (8.86)</td><td align="left" colspan="1" rowspan="1">35,712 (26.97)</td><td align="left" colspan="1" rowspan="1">41,644 (31.45)</td><td align="left" colspan="1" rowspan="1">22,335 (16.87)</td><td align="left" colspan="1" rowspan="1">59,244</td><td align="left" colspan="1" rowspan="1">40</td><td align="left" colspan="1" rowspan="1">0.68</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">19,352</td><td align="left" colspan="1" rowspan="1">8856 (45.76)</td><td align="left" colspan="1" rowspan="1">10,408 (53.78)</td><td align="left" colspan="1" rowspan="1">1698 (8.77)</td><td align="left" colspan="1" rowspan="1">1790 (9.25)</td><td align="left" colspan="1" rowspan="1">5816 (30.05)</td><td align="left" colspan="1" rowspan="1">6739 (34.82)</td><td align="left" colspan="1" rowspan="1">2936 (15.17)</td><td align="left" colspan="1" rowspan="1">9101</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;5</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.55</td></tr><tr><td align="left" rowspan="2" colspan="1">Italy IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">48,983</td><td align="left" colspan="1" rowspan="1">18,693 (38.16)</td><td align="left" colspan="1" rowspan="1">25,843 (52.76)</td><td align="left" colspan="1" rowspan="1">1088 (2.22)</td><td align="left" colspan="1" rowspan="1">2952 (6.03)</td><td align="left" colspan="1" rowspan="1">12,077 (24.66)</td><td align="left" colspan="1" rowspan="1">19,663 (40.14)</td><td align="left" colspan="1" rowspan="1">13,044 (26.63)</td><td align="left" colspan="1" rowspan="1">22,273</td><td align="left" colspan="1" rowspan="1">17</td><td align="left" colspan="1" rowspan="1">0.76</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">8413</td><td align="left" colspan="1" rowspan="1">3196 (37.99)</td><td align="left" colspan="1" rowspan="1">4326 (51.42)</td><td align="left" colspan="1" rowspan="1">367 (4.36)</td><td align="left" colspan="1" rowspan="1">488 (5.80)</td><td align="left" colspan="1" rowspan="1">2035 (24.19)</td><td align="left" colspan="1" rowspan="1">3435 (40.83)</td><td align="left" colspan="1" rowspan="1">2000 (23.77)</td><td align="left" colspan="1" rowspan="1">3782</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;5</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;1.32</td></tr><tr><td align="left" rowspan="2" colspan="1">UK IMRD</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">311,440</td><td align="left" colspan="1" rowspan="1">134,066 (43.05)</td><td align="left" colspan="1" rowspan="1">175,264 (56.28)</td><td align="left" colspan="1" rowspan="1">35,421 (11.37)</td><td align="left" colspan="1" rowspan="1">31,415 (10.09)</td><td align="left" colspan="1" rowspan="1">97,459 (31.29)</td><td align="left" colspan="1" rowspan="1">96,449 (30.97)</td><td align="left" colspan="1" rowspan="1">42,754 (13.763)</td><td align="left" colspan="1" rowspan="1">137,275</td><td align="left" colspan="1" rowspan="1">40</td><td align="left" colspan="1" rowspan="1">0.29</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">35,767</td><td align="left" colspan="1" rowspan="1">15,502 (43.34)</td><td align="left" colspan="1" rowspan="1">20,238 (56.58)</td><td align="left" colspan="1" rowspan="1">3844 (10.75)</td><td align="left" colspan="1" rowspan="1">3699 (10.34)</td><td align="left" colspan="1" rowspan="1">11,127 (31.11)</td><td align="left" colspan="1" rowspan="1">11,220 (31.37)</td><td align="left" colspan="1" rowspan="1">5765 (16.12)</td><td align="left" colspan="1" rowspan="1">16,390</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">0.49</td></tr><tr><td align="left" rowspan="2" colspan="1">US PharMetrics Plus</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">651,274</td><td align="left" colspan="1" rowspan="1">298,733 (45.87)</td><td align="left" colspan="1" rowspan="1">345,851 (53.10)</td><td align="left" colspan="1" rowspan="1">68,213 (10.47)</td><td align="left" colspan="1" rowspan="1">80,893 (12.42)</td><td align="left" colspan="1" rowspan="1">208,434 (32.00)</td><td align="left" colspan="1" rowspan="1">226,625 (34.80)</td><td align="left" colspan="1" rowspan="1">45,831 (7.04)</td><td align="left" colspan="1" rowspan="1">281,063</td><td align="left" colspan="1" rowspan="1">1382</td><td align="left" colspan="1" rowspan="1">4.92</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">137,994</td><td align="left" colspan="1" rowspan="1">63,730 (46.18)</td><td align="left" colspan="1" rowspan="1">72,543 (52.60)</td><td align="left" colspan="1" rowspan="1">11,163 (8.09)</td><td align="left" colspan="1" rowspan="1">18,028 (13.06)</td><td align="left" colspan="1" rowspan="1">44,766 (32.44)</td><td align="left" colspan="1" rowspan="1">49,562 (35.92)</td><td align="left" colspan="1" rowspan="1">8817 (6.39)</td><td align="left" colspan="1" rowspan="1">63,265</td><td align="left" colspan="1" rowspan="1">307</td><td align="left" colspan="1" rowspan="1">4.85</td></tr><tr><td align="left" rowspan="10" colspan="1"><bold>Psychoses</bold></td><td align="left" rowspan="2" colspan="1">France IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">367,222</td><td align="left" colspan="1" rowspan="1">157,237 (42.82)</td><td align="left" colspan="1" rowspan="1">205,529 (55.97)</td><td align="left" colspan="1" rowspan="1">33,452 (9.11)</td><td align="left" colspan="1" rowspan="1">30,949 (8.43)</td><td align="left" colspan="1" rowspan="1">107,493 (29.27)</td><td align="left" colspan="1" rowspan="1">124,791 (33.98)</td><td align="left" colspan="1" rowspan="1">60,072 (16.36)</td><td align="left" colspan="1" rowspan="1">16,1528</td><td align="left" colspan="1" rowspan="1">190</td><td align="left" colspan="1" rowspan="1">1.18</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">53,576</td><td align="left" colspan="1" rowspan="1">22,531 (42.05)</td><td align="left" colspan="1" rowspan="1">30,312 (56.58)</td><td align="left" colspan="1" rowspan="1">4498 (8.40)</td><td align="left" colspan="1" rowspan="1">4230 (7.90)</td><td align="left" colspan="1" rowspan="1">15,921 (29.72)</td><td align="left" colspan="1" rowspan="1">18,529 (34.58)</td><td align="left" colspan="1" rowspan="1">7513 (14.02)</td><td align="left" colspan="1" rowspan="1">24,531</td><td align="left" colspan="1" rowspan="1">27</td><td align="left" colspan="1" rowspan="1">1.1</td></tr><tr><td align="left" rowspan="2" colspan="1">Germany IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">132,002</td><td align="left" colspan="1" rowspan="1">59,113 (44.79)</td><td align="left" colspan="1" rowspan="1">70,571 (53.46)</td><td align="left" colspan="1" rowspan="1">13,771 (10.43)</td><td align="left" colspan="1" rowspan="1">11,723 (8.88)</td><td align="left" colspan="1" rowspan="1">35,634 (27.00)</td><td align="left" colspan="1" rowspan="1">41,507 (31.44)</td><td align="left" colspan="1" rowspan="1">22,116 (16.75)</td><td align="left" colspan="1" rowspan="1">59,031</td><td align="left" colspan="1" rowspan="1">172</td><td align="left" colspan="1" rowspan="1">2.91</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">19,301</td><td align="left" colspan="1" rowspan="1">8836 (45.78)</td><td align="left" colspan="1" rowspan="1">10,376 (53.76)</td><td align="left" colspan="1" rowspan="1">1697 (8.79)</td><td align="left" colspan="1" rowspan="1">1788 (9.26)</td><td align="left" colspan="1" rowspan="1">5806 (30.08)</td><td align="left" colspan="1" rowspan="1">6735 (34.89)</td><td align="left" colspan="1" rowspan="1">2913 (15.09)</td><td align="left" colspan="1" rowspan="1">9075</td><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">1.21</td></tr><tr><td align="left" rowspan="2" colspan="1">Italy IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">48,921</td><td align="left" colspan="1" rowspan="1">18,674 (38.17)</td><td align="left" colspan="1" rowspan="1">25,828 (52.80)</td><td align="left" colspan="1" rowspan="1">1075 (2.20)</td><td align="left" colspan="1" rowspan="1">2952 (6.03)</td><td align="left" colspan="1" rowspan="1">12,117 (24.77)</td><td align="left" colspan="1" rowspan="1">19,643 (40.15)</td><td align="left" colspan="1" rowspan="1">12,953 (26.48)</td><td align="left" colspan="1" rowspan="1">22,244</td><td align="left" colspan="1" rowspan="1">30</td><td align="left" colspan="1" rowspan="1">1.35</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">8404</td><td align="left" colspan="1" rowspan="1">3189 (37.95)</td><td align="left" colspan="1" rowspan="1">4324 (51.45)</td><td align="left" colspan="1" rowspan="1">399 (4.75)</td><td align="left" colspan="1" rowspan="1">487 (5.79)</td><td align="left" colspan="1" rowspan="1">2038 (24.25)</td><td align="left" colspan="1" rowspan="1">3433 (40.85)</td><td align="left" colspan="1" rowspan="1">1988 (23.66)</td><td align="left" colspan="1" rowspan="1">3775</td><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">2.91</td></tr><tr><td align="left" rowspan="2" colspan="1">UK IMRD</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">311,286</td><td align="left" colspan="1" rowspan="1">134,004 (43.05)</td><td align="left" colspan="1" rowspan="1">175,190 (56.28)</td><td align="left" colspan="1" rowspan="1">35,411 (11.38)</td><td align="left" colspan="1" rowspan="1">31,403 (10.09)</td><td align="left" colspan="1" rowspan="1">97,472 (31.31)</td><td align="left" colspan="1" rowspan="1">96,417 (30.97)</td><td align="left" colspan="1" rowspan="1">42,695 (13.72)</td><td align="left" colspan="1" rowspan="1">137,187</td><td align="left" colspan="1" rowspan="1">111</td><td align="left" colspan="1" rowspan="1">0.81</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">35,751</td><td align="left" colspan="1" rowspan="1">15,496 (43.34)</td><td align="left" colspan="1" rowspan="1">20,227 (56.58)</td><td align="left" colspan="1" rowspan="1">3842 (10.75)</td><td align="left" colspan="1" rowspan="1">3697 (10.34)</td><td align="left" colspan="1" rowspan="1">11,129 (31.13)</td><td align="left" colspan="1" rowspan="1">11,219 (31.38)</td><td align="left" colspan="1" rowspan="1">5751 (16.09)</td><td align="left" colspan="1" rowspan="1">16,384</td><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">0.67</td></tr><tr><td align="left" rowspan="2" colspan="1">US PharMetrics Plus</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">655,719</td><td align="left" colspan="1" rowspan="1">299,889 (45.73)</td><td align="left" colspan="1" rowspan="1">349,050 (53.23)</td><td align="left" colspan="1" rowspan="1">68,363 (10.43)</td><td align="left" colspan="1" rowspan="1">81,663 (12.45)</td><td align="left" colspan="1" rowspan="1">210,632 (31.12)</td><td align="left" colspan="1" rowspan="1">228,218 (34.80)</td><td align="left" colspan="1" rowspan="1">45,599 (6.95)</td><td align="left" colspan="1" rowspan="1">283,167</td><td align="left" colspan="1" rowspan="1">536</td><td align="left" colspan="1" rowspan="1">1.89</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">138,882</td><td align="left" colspan="1" rowspan="1">63,981 (46.07)</td><td align="left" colspan="1" rowspan="1">73,175 (52.69)</td><td align="left" colspan="1" rowspan="1">11,187 (8.06)</td><td align="left" colspan="1" rowspan="1">18,163 (13.08)</td><td align="left" colspan="1" rowspan="1">45,099 (32.47)</td><td align="left" colspan="1" rowspan="1">49,922 (35.95)</td><td align="left" colspan="1" rowspan="1">8757 (6.31)</td><td align="left" colspan="1" rowspan="1">63,715</td><td align="left" colspan="1" rowspan="1">175</td><td align="left" colspan="1" rowspan="1">2.75</td></tr><tr><td align="left" rowspan="10" colspan="1"><bold>Personality disorders</bold></td><td align="left" rowspan="2" colspan="1">France IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">367,882</td><td align="left" colspan="1" rowspan="1">157,565 (42.83)</td><td align="left" colspan="1" rowspan="1">205,832 (55.95)</td><td align="left" colspan="1" rowspan="1">33,444 (9.09)</td><td align="left" colspan="1" rowspan="1">30,951 (8.41)</td><td align="left" colspan="1" rowspan="1">107,663 (29.27)</td><td align="left" colspan="1" rowspan="1">125,103 (34.01)</td><td align="left" colspan="1" rowspan="1">60,257 (16.38)</td><td align="left" colspan="1" rowspan="1">161,848</td><td align="left" colspan="1" rowspan="1">60</td><td align="left" colspan="1" rowspan="1">0.37</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">53,662</td><td align="left" colspan="1" rowspan="1">22,576 (42.07)</td><td align="left" colspan="1" rowspan="1">30,359 (56.57)</td><td align="left" colspan="1" rowspan="1">4497 (8.38)</td><td align="left" colspan="1" rowspan="1">4230 (7.88)</td><td align="left" colspan="1" rowspan="1">15,943 (29.71)</td><td align="left" colspan="1" rowspan="1">18,572 (34.61)</td><td align="left" colspan="1" rowspan="1">7531 (14.03)</td><td align="left" colspan="1" rowspan="1">24,576</td><td align="left" colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">0.53</td></tr><tr><td align="left" rowspan="2" colspan="1">Germany IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">132,010</td><td align="left" colspan="1" rowspan="1">59,073 (44.75)</td><td align="left" colspan="1" rowspan="1">70,629 (53.50)</td><td align="left" colspan="1" rowspan="1">13,753 (10.42)</td><td align="left" colspan="1" rowspan="1">11,733 (8.89)</td><td align="left" colspan="1" rowspan="1">35,585 (26.96)</td><td align="left" colspan="1" rowspan="1">41,464 (31.41)</td><td align="left" colspan="1" rowspan="1">22,259 (16.86)</td><td align="left" colspan="1" rowspan="1">59,010</td><td align="left" colspan="1" rowspan="1">251</td><td align="left" colspan="1" rowspan="1">4.25</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">19,305</td><td align="left" colspan="1" rowspan="1">8834 (45.76)</td><td align="left" colspan="1" rowspan="1">10,382 (45.76)</td><td align="left" colspan="1" rowspan="1">1697 (8.79)</td><td align="left" colspan="1" rowspan="1">1788 (9.26)</td><td align="left" colspan="1" rowspan="1">5800 (30.04)</td><td align="left" colspan="1" rowspan="1">6727 (34.85)</td><td align="left" colspan="1" rowspan="1">2930 (15.18)</td><td align="left" colspan="1" rowspan="1">9071</td><td align="left" colspan="1" rowspan="1">32</td><td align="left" colspan="1" rowspan="1">3.53</td></tr><tr><td align="left" rowspan="2" colspan="1">Italy IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">48,481</td><td align="left" colspan="1" rowspan="1">18,536 (38.23)</td><td align="left" colspan="1" rowspan="1">25,590 (52.78)</td><td align="left" colspan="1" rowspan="1">1118 (2.31)</td><td align="left" colspan="1" rowspan="1">2952 (6.09)</td><td align="left" colspan="1" rowspan="1">12,111 (24.98)</td><td align="left" colspan="1" rowspan="1">19,608 (40.44)</td><td align="left" colspan="1" rowspan="1">12,589 (25.97)</td><td align="left" colspan="1" rowspan="1">22,025</td><td align="left" colspan="1" rowspan="1">152</td><td align="left" colspan="1" rowspan="1">6.9</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">8327</td><td align="left" colspan="1" rowspan="1">3164 (38.00)</td><td align="left" colspan="1" rowspan="1">4284 (51.45)</td><td align="left" colspan="1" rowspan="1">396 (4.76)</td><td align="left" colspan="1" rowspan="1">489 (5.87)</td><td align="left" colspan="1" rowspan="1">2038 (24.47)</td><td align="left" colspan="1" rowspan="1">3423 (41.11)</td><td align="left" colspan="1" rowspan="1">1922 (23.08)</td><td align="left" colspan="1" rowspan="1">3739</td><td align="left" colspan="1" rowspan="1">39</td><td align="left" colspan="1" rowspan="1">10.43</td></tr><tr><td align="left" rowspan="2" colspan="1">UK IMRD</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">311,272</td><td align="left" colspan="1" rowspan="1">134,031 (43.06)</td><td align="left" colspan="1" rowspan="1">175,128 (56.26)</td><td align="left" colspan="1" rowspan="1">35,411 (11.38)</td><td align="left" colspan="1" rowspan="1">31,345 (10.07)</td><td align="left" colspan="1" rowspan="1">97,450 (31.31)</td><td align="left" colspan="1" rowspan="1">96,375 (30.96)</td><td align="left" colspan="1" rowspan="1">42,746 (13.73)</td><td align="left" colspan="1" rowspan="1">137,186</td><td align="left" colspan="1" rowspan="1">84</td><td align="left" colspan="1" rowspan="1">0.61</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">35,753</td><td align="left" colspan="1" rowspan="1">15,500 (43.35)</td><td align="left" colspan="1" rowspan="1">20,227 (56.57)</td><td align="left" colspan="1" rowspan="1">3843 (10.75)</td><td align="left" colspan="1" rowspan="1">3691 (10.32)</td><td align="left" colspan="1" rowspan="1">11,130 (31.13)</td><td align="left" colspan="1" rowspan="1">11,214 (31.37)</td><td align="left" colspan="1" rowspan="1">5764 (16.12)</td><td align="left" colspan="1" rowspan="1">16,381</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">0.92</td></tr><tr><td align="left" rowspan="2" colspan="1">US PharMetrics Plus</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">656,469</td><td align="left" colspan="1" rowspan="1">300,441 (45.77)</td><td align="left" colspan="1" rowspan="1">349,260 (53.20)</td><td align="left" colspan="1" rowspan="1">68,259 (10.40)</td><td align="left" colspan="1" rowspan="1">81,435 (12.41)</td><td align="left" colspan="1" rowspan="1">210,520 (32.07)</td><td align="left" colspan="1" rowspan="1">228,569 (34.82)</td><td align="left" colspan="1" rowspan="1">46,260 (7.05)</td><td align="left" colspan="1" rowspan="1">283,419</td><td align="left" colspan="1" rowspan="1">570</td><td align="left" colspan="1" rowspan="1">2.01</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">139,016</td><td align="left" colspan="1" rowspan="1">64,080 (46.10)</td><td align="left" colspan="1" rowspan="1">73,211 (52.66)</td><td align="left" colspan="1" rowspan="1">11,173 (8.04)</td><td align="left" colspan="1" rowspan="1">18,127 (13.04)</td><td align="left" colspan="1" rowspan="1">45,085 (32.43)</td><td align="left" colspan="1" rowspan="1">49,961 (35.94)</td><td align="left" colspan="1" rowspan="1">8907 (6.41)</td><td align="left" colspan="1" rowspan="1">63,793</td><td align="left" colspan="1" rowspan="1">78</td><td align="left" colspan="1" rowspan="1">1.22</td></tr><tr><td align="left" rowspan="10" colspan="1"><bold>Self-harm and suicide</bold></td><td align="left" rowspan="2" colspan="1">France IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">367,961</td><td align="left" colspan="1" rowspan="1">157,640 (42.84)</td><td align="left" colspan="1" rowspan="1">205,853 (55.94)</td><td align="left" colspan="1" rowspan="1">33,443 (9.09)</td><td align="left" colspan="1" rowspan="1">30,958 (8.41)</td><td align="left" colspan="1" rowspan="1">107,701 (29.27)</td><td align="left" colspan="1" rowspan="1">125,091 (34.00)</td><td align="left" colspan="1" rowspan="1">60,280 (16.38)</td><td align="left" colspan="1" rowspan="1">161,887</td><td align="left" colspan="1" rowspan="1">44</td><td align="left" colspan="1" rowspan="1">0.27</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">53,676</td><td align="left" colspan="1" rowspan="1">22,586 (42.08)</td><td align="left" colspan="1" rowspan="1">30,359 (56.56)</td><td align="left" colspan="1" rowspan="1">4496 (8.38)</td><td align="left" colspan="1" rowspan="1">4232 (7.88)</td><td align="left" colspan="1" rowspan="1">15,950 (29.72)</td><td align="left" colspan="1" rowspan="1">18,573 (34.60)</td><td align="left" colspan="1" rowspan="1">7535 (14.04)</td><td align="left" colspan="1" rowspan="1">24,584</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;10</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.41</td></tr><tr><td align="left" rowspan="2" colspan="1">Germany IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">132,538</td><td align="left" colspan="1" rowspan="1">59,319 (44.76)</td><td align="left" colspan="1" rowspan="1">70,927 (53.51)</td><td align="left" colspan="1" rowspan="1">13,773 (10.39)</td><td align="left" colspan="1" rowspan="1">11,749 (8.86)</td><td align="left" colspan="1" rowspan="1">35,727 (26.96)</td><td align="left" colspan="1" rowspan="1">41,680 (31.45)</td><td align="left" colspan="1" rowspan="1">22,376 (16.88)</td><td align="left" colspan="1" rowspan="1">59,307</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;5</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.08</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">19,366</td><td align="left" colspan="1" rowspan="1">8861 (45.76)</td><td align="left" colspan="1" rowspan="1">10,417 (53.79)</td><td align="left" colspan="1" rowspan="1">1698 (8.77)</td><td align="left" colspan="1" rowspan="1">1790 (9.24)</td><td align="left" colspan="1" rowspan="1">5819 (30.05)</td><td align="left" colspan="1" rowspan="1">6753 (34.87)</td><td align="left" colspan="1" rowspan="1">2940 (15.18)</td><td align="left" colspan="1" rowspan="1">9108</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0</td></tr><tr><td align="left" rowspan="2" colspan="1">Italy IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">49,144</td><td align="left" colspan="1" rowspan="1">18,755 (38.16)</td><td align="left" colspan="1" rowspan="1">25,943 (52.79)</td><td align="left" colspan="1" rowspan="1">1166 (2.37)</td><td align="left" colspan="1" rowspan="1">2953 (6.01)</td><td align="left" colspan="1" rowspan="1">12,148 (24.72)</td><td align="left" colspan="1" rowspan="1">19,721 (40.13)</td><td align="left" colspan="1" rowspan="1">13,071 (26.60)</td><td align="left" colspan="1" rowspan="1">22,353</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">8444</td><td align="left" colspan="1" rowspan="1">3204 (37.94)</td><td align="left" colspan="1" rowspan="1">4345 (51.46)</td><td align="left" colspan="1" rowspan="1">400 (4.74)</td><td align="left" colspan="1" rowspan="1">489 (5.79)</td><td align="left" colspan="1" rowspan="1">2044 (24.21)</td><td align="left" colspan="1" rowspan="1">3446 (40.81)</td><td align="left" colspan="1" rowspan="1">2004 (23.73)</td><td align="left" colspan="1" rowspan="1">3795</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0</td></tr><tr><td align="left" rowspan="2" colspan="1">UK IMRD</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">311,149</td><td align="left" colspan="1" rowspan="1">133,975 (43.06)</td><td align="left" colspan="1" rowspan="1">175,058 (56.26)</td><td align="left" colspan="1" rowspan="1">35,342 (11.36)</td><td align="left" colspan="1" rowspan="1">31,338 (10.07)</td><td align="left" colspan="1" rowspan="1">97,414 (31.31)</td><td align="left" colspan="1" rowspan="1">96,417 (30.99)</td><td align="left" colspan="1" rowspan="1">42,692 (13.72)</td><td align="left" colspan="1" rowspan="1">137,127</td><td align="left" colspan="1" rowspan="1">140</td><td align="left" colspan="1" rowspan="1">1.02</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">35,732</td><td align="left" colspan="1" rowspan="1">15,493 (43.36)</td><td align="left" colspan="1" rowspan="1">20,212 (56.57)</td><td align="left" colspan="1" rowspan="1">3835 (10.73)</td><td align="left" colspan="1" rowspan="1">3690 (10.33)</td><td align="left" colspan="1" rowspan="1">11,121 (31.12)</td><td align="left" colspan="1" rowspan="1">11,218 (31.39)</td><td align="left" colspan="1" rowspan="1">5756 (14.11)</td><td align="left" colspan="1" rowspan="1">16,373</td><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">0.86</td></tr><tr><td align="left" rowspan="2" colspan="1">US PharMetrics Plus</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">657,634</td><td align="left" colspan="1" rowspan="1">300,838 (45.75)</td><td align="left" colspan="1" rowspan="1">350,011 (53.22)</td><td align="left" colspan="1" rowspan="1">68,341 (10.39)</td><td align="left" colspan="1" rowspan="1">81,747 (12.43)</td><td align="left" colspan="1" rowspan="1">211,021 (32.09)</td><td align="left" colspan="1" rowspan="1">228,782 (34.79)</td><td align="left" colspan="1" rowspan="1">46,327 (7.04)</td><td align="left" colspan="1" rowspan="1">283,995</td><td align="left" colspan="1" rowspan="1">243</td><td align="left" colspan="1" rowspan="1">0.86</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">139,239</td><td align="left" colspan="1" rowspan="1">64,148 (46.07)</td><td align="left" colspan="1" rowspan="1">73,356 (52.68)</td><td align="left" colspan="1" rowspan="1">11,182 (8.03)</td><td align="left" colspan="1" rowspan="1">18,170 (13.05)</td><td align="left" colspan="1" rowspan="1">45,171 (32.44)</td><td align="left" colspan="1" rowspan="1">50,013 (35.92)</td><td align="left" colspan="1" rowspan="1">8928 (6.41)</td><td align="left" colspan="1" rowspan="1">63,889</td><td align="left" colspan="1" rowspan="1">69</td><td align="left" colspan="1" rowspan="1">1.08</td></tr><tr><td align="left" rowspan="10" colspan="1"><bold>Sleep disorders</bold></td><td align="left" rowspan="2" colspan="1">France IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">350,031</td><td align="left" colspan="1" rowspan="1">151,096 (43.17)</td><td align="left" colspan="1" rowspan="1">195,052 (55.72)</td><td align="left" colspan="1" rowspan="1">33,106 (9.46)</td><td align="left" colspan="1" rowspan="1">30,350 (8.67)</td><td align="left" colspan="1" rowspan="1">104,273 (29.79)</td><td align="left" colspan="1" rowspan="1">117,993 (33.71)</td><td align="left" colspan="1" rowspan="1">54,745 (15.64)</td><td align="left" colspan="1" rowspan="1">152,814</td><td align="left" colspan="1" rowspan="1">4444</td><td align="left" colspan="1" rowspan="1">29.08</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">51,025</td><td align="left" colspan="1" rowspan="1">21,635 (42.40)</td><td align="left" colspan="1" rowspan="1">28,672 (56.19)</td><td align="left" colspan="1" rowspan="1">4450 (8.72)</td><td align="left" colspan="1" rowspan="1">4142 (8.12)</td><td align="left" colspan="1" rowspan="1">15,385 (30.15)</td><td align="left" colspan="1" rowspan="1">17,476 (34.25)</td><td align="left" colspan="1" rowspan="1">6814 (13.35)</td><td align="left" colspan="1" rowspan="1">23,047</td><td align="left" colspan="1" rowspan="1">1056</td><td align="left" colspan="1" rowspan="1">45.82</td></tr><tr><td align="left" rowspan="2" colspan="1">Germany IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">127,308</td><td align="left" colspan="1" rowspan="1">56,831 (44.64)</td><td align="left" colspan="1" rowspan="1">68,233 (53.60)</td><td align="left" colspan="1" rowspan="1">13,680 (10.75)</td><td align="left" colspan="1" rowspan="1">11,583 (9.10)</td><td align="left" colspan="1" rowspan="1">34,710 (27.26)</td><td align="left" colspan="1" rowspan="1">39,731 (31.21)</td><td align="left" colspan="1" rowspan="1">20,699 (16.26)</td><td align="left" colspan="1" rowspan="1">56,322</td><td align="left" colspan="1" rowspan="1">2182</td><td align="left" colspan="1" rowspan="1">38.74</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">18,658</td><td align="left" colspan="1" rowspan="1">8505 (45.58)</td><td align="left" colspan="1" rowspan="1">10,027 (53.74)</td><td align="left" colspan="1" rowspan="1">1682 (9.01)</td><td align="left" colspan="1" rowspan="1">1770 (9.49)</td><td align="left" colspan="1" rowspan="1">5671 (30.39)</td><td align="left" colspan="1" rowspan="1">6466 (34.66)</td><td align="left" colspan="1" rowspan="1">2713 (14.54)</td><td align="left" colspan="1" rowspan="1">8679</td><td align="left" colspan="1" rowspan="1">360</td><td align="left" colspan="1" rowspan="1">41.48</td></tr><tr><td align="left" rowspan="2" colspan="1">Italy IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">47,108</td><td align="left" colspan="1" rowspan="1">18,078 (38.38)</td><td align="left" colspan="1" rowspan="1">24,718 (52.47)</td><td align="left" colspan="1" rowspan="1">1124 (2.39)</td><td align="left" colspan="1" rowspan="1">2942 (6.25)</td><td align="left" colspan="1" rowspan="1">11,962 (25.39)</td><td align="left" colspan="1" rowspan="1">18,973 (40.28)</td><td align="left" colspan="1" rowspan="1">12,022 (25.52)</td><td align="left" colspan="1" rowspan="1">21,334</td><td align="left" colspan="1" rowspan="1">424</td><td align="left" colspan="1" rowspan="1">19.57</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">8081</td><td align="left" colspan="1" rowspan="1">3085 (38.17)</td><td align="left" colspan="1" rowspan="1">4142 (51.26)</td><td align="left" colspan="1" rowspan="1">378 (4.68)</td><td align="left" colspan="1" rowspan="1">488 (6.04)</td><td align="left" colspan="1" rowspan="1">2011 (24.89)</td><td align="left" colspan="1" rowspan="1">3293 (40.75)</td><td align="left" colspan="1" rowspan="1">1850 (22.89)</td><td align="left" colspan="1" rowspan="1">3596</td><td align="left" colspan="1" rowspan="1">132</td><td align="left" colspan="1" rowspan="1">36.7</td></tr><tr><td align="left" rowspan="2" colspan="1">UK IMRD</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">309,291</td><td align="left" colspan="1" rowspan="1">133,171 (43.06)</td><td align="left" colspan="1" rowspan="1">174,083 (56.28)</td><td align="left" colspan="1" rowspan="1">35,342 (11.43)</td><td align="left" colspan="1" rowspan="1">31,294 (10.12)</td><td align="left" colspan="1" rowspan="1">86,887 (28.09)</td><td align="left" colspan="1" rowspan="1">95,649 (30.93)</td><td align="left" colspan="1" rowspan="1">42,224 (13.65)</td><td align="left" colspan="1" rowspan="1">136,147</td><td align="left" colspan="1" rowspan="1">902</td><td align="left" colspan="1" rowspan="1">6.63</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">35,526</td><td align="left" colspan="1" rowspan="1">15,399 (43.35)</td><td align="left" colspan="1" rowspan="1">20,102 (56.58)</td><td align="left" colspan="1" rowspan="1">3837 (10.80)</td><td align="left" colspan="1" rowspan="1">3682 (10.36)</td><td align="left" colspan="1" rowspan="1">11,065 (31.15)</td><td align="left" colspan="1" rowspan="1">11,131 (31.33)</td><td align="left" colspan="1" rowspan="1">5699 (16.04)</td><td align="left" colspan="1" rowspan="1">16,254</td><td align="left" colspan="1" rowspan="1">132</td><td align="left" colspan="1" rowspan="1">8.12</td></tr><tr><td align="left" rowspan="2" colspan="1">US PharMetrics Plus</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">592,830</td><td align="left" colspan="1" rowspan="1">269,300 (45.43)</td><td align="left" colspan="1" rowspan="1">317,217 (53.51)</td><td align="left" colspan="1" rowspan="1">66,595 (11.23)</td><td align="left" colspan="1" rowspan="1">79,047 (13.33)</td><td align="left" colspan="1" rowspan="1">195,609 (33.00)</td><td align="left" colspan="1" rowspan="1">195,813 (33.03)</td><td align="left" colspan="1" rowspan="1">37,291 (6.29)</td><td align="left" colspan="1" rowspan="1">252,186</td><td align="left" colspan="1" rowspan="1">16,962</td><td align="left" colspan="1" rowspan="1">67.26</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">126,034</td><td align="left" colspan="1" rowspan="1">57,857 (45.91)</td><td align="left" colspan="1" rowspan="1">66,575 (52.82)</td><td align="left" colspan="1" rowspan="1">10,911 (8.66)</td><td align="left" colspan="1" rowspan="1">17,643 (14.00)</td><td align="left" colspan="1" rowspan="1">42,013 (33.33)</td><td align="left" colspan="1" rowspan="1">43,026 (34.14)</td><td align="left" colspan="1" rowspan="1">7191 (5.71)</td><td align="left" colspan="1" rowspan="1">56,538</td><td align="left" colspan="1" rowspan="1">4802</td><td align="left" colspan="1" rowspan="1">84.87</td></tr><tr><td align="left" rowspan="10" colspan="1"><bold>Dementia</bold></td><td align="left" rowspan="2" colspan="1">France IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">367,141</td><td align="left" colspan="1" rowspan="1">157,365 (42.86)</td><td align="left" colspan="1" rowspan="1">205,349 (55.93)</td><td align="left" colspan="1" rowspan="1">33,454 (9.11)</td><td align="left" colspan="1" rowspan="1">30,962 (8.43)</td><td align="left" colspan="1" rowspan="1">107,694 (29.33)</td><td align="left" colspan="1" rowspan="1">125,094 (34.07)</td><td align="left" colspan="1" rowspan="1">59,533 (16.22)</td><td align="left" colspan="1" rowspan="1">161,555</td><td align="left" colspan="1" rowspan="1">87</td><td align="left" colspan="1" rowspan="1">0.54</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">53,582</td><td align="left" colspan="1" rowspan="1">22,558 (42.10)</td><td align="left" colspan="1" rowspan="1">30,295 (56.54)</td><td align="left" colspan="1" rowspan="1">4498 (8.39)</td><td align="left" colspan="1" rowspan="1">4233 (7.90)</td><td align="left" colspan="1" rowspan="1">15,950 (29.77)</td><td align="left" colspan="1" rowspan="1">18,571 (34.66)</td><td align="left" colspan="1" rowspan="1">7450 (13.90)</td><td align="left" colspan="1" rowspan="1">24,544</td><td align="left" colspan="1" rowspan="1">23</td><td align="left" colspan="1" rowspan="1">0.94</td></tr><tr><td align="left" rowspan="2" colspan="1">Germany IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">130,548</td><td align="left" colspan="1" rowspan="1">58,726 (44.98)</td><td align="left" colspan="1" rowspan="1">69,559 (53.28)</td><td align="left" colspan="1" rowspan="1">13,782 (10.56)</td><td align="left" colspan="1" rowspan="1">11,748 (9.00)</td><td align="left" colspan="1" rowspan="1">35,711 (27.35)</td><td align="left" colspan="1" rowspan="1">41,585 (31.85)</td><td align="left" colspan="1" rowspan="1">20,516 (15.72)</td><td align="left" colspan="1" rowspan="1">58,364</td><td align="left" colspan="1" rowspan="1">387</td><td align="left" colspan="1" rowspan="1">6.63</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">19,132</td><td align="left" colspan="1" rowspan="1">8794 (45.96)</td><td align="left" colspan="1" rowspan="1">10,251 (53.58)</td><td align="left" colspan="1" rowspan="1">1697 (8.87)</td><td align="left" colspan="1" rowspan="1">1790 (9.36)</td><td align="left" colspan="1" rowspan="1">5818 (30.41)</td><td align="left" colspan="1" rowspan="1">6743 (35.24)</td><td align="left" colspan="1" rowspan="1">2719 (14.21)</td><td align="left" colspan="1" rowspan="1">8999</td><td align="left" colspan="1" rowspan="1">50</td><td align="left" colspan="1" rowspan="1">5.56</td></tr><tr><td align="left" rowspan="2" colspan="1">Italy IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">48,815</td><td align="left" colspan="1" rowspan="1">18,660 (38.23)</td><td align="left" colspan="1" rowspan="1">25,733 (52.72)</td><td align="left" colspan="1" rowspan="1">1200 (2.46)</td><td align="left" colspan="1" rowspan="1">2953 (6.05)</td><td align="left" colspan="1" rowspan="1">12,148 (24.89)</td><td align="left" colspan="1" rowspan="1">19,720 (40.40)</td><td align="left" colspan="1" rowspan="1">12,727 (26.07)</td><td align="left" colspan="1" rowspan="1">22,204</td><td align="left" colspan="1" rowspan="1">57</td><td align="left" colspan="1" rowspan="1">2.57</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">8391</td><td align="left" colspan="1" rowspan="1">3189 (38.00)</td><td align="left" colspan="1" rowspan="1">4312 (51.39)</td><td align="left" colspan="1" rowspan="1">399 (4.76)</td><td align="left" colspan="1" rowspan="1">489 (5.83)</td><td align="left" colspan="1" rowspan="1">2044 (24.36)</td><td align="left" colspan="1" rowspan="1">3446 (41.07)</td><td align="left" colspan="1" rowspan="1">1957 (23.32)</td><td align="left" colspan="1" rowspan="1">3777</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">2.12</td></tr><tr><td align="left" rowspan="2" colspan="1">UK IMRD</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">307,701</td><td align="left" colspan="1" rowspan="1">132,779 (43.15)</td><td align="left" colspan="1" rowspan="1">172,882 (56.19)</td><td align="left" colspan="1" rowspan="1">35,411 (11.51)</td><td align="left" colspan="1" rowspan="1">31,413 (10.21)</td><td align="left" colspan="1" rowspan="1">97,502 (31.69)</td><td align="left" colspan="1" rowspan="1">96,370 (31.32)</td><td align="left" colspan="1" rowspan="1">39,552 (12.85)</td><td align="left" colspan="1" rowspan="1">135,856</td><td align="left" colspan="1" rowspan="1">471</td><td align="left" colspan="1" rowspan="1">3.47</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">35,263</td><td align="left" colspan="1" rowspan="1">15,304 (43.40)</td><td align="left" colspan="1" rowspan="1">19,932 (56.52)</td><td align="left" colspan="1" rowspan="1">3841 (10.89)</td><td align="left" colspan="1" rowspan="1">3699 (10.49)</td><td align="left" colspan="1" rowspan="1">11,133 (31.57)</td><td align="left" colspan="1" rowspan="1">11,212 (31.80)</td><td align="left" colspan="1" rowspan="1">5262 (14.92)</td><td align="left" colspan="1" rowspan="1">16,203</td><td align="left" colspan="1" rowspan="1">125</td><td align="left" colspan="1" rowspan="1">7.71</td></tr><tr><td align="left" rowspan="2" colspan="1">US PharMetrics Plus</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">649,692</td><td align="left" colspan="1" rowspan="1">298,235 (45.90)</td><td align="left" colspan="1" rowspan="1">345,059 (53.11)</td><td align="left" colspan="1" rowspan="1">68,330 (10.52)</td><td align="left" colspan="1" rowspan="1">81,713 (12.58)</td><td align="left" colspan="1" rowspan="1">210,633 (32.42)</td><td align="left" colspan="1" rowspan="1">229,161 (35.27)</td><td align="left" colspan="1" rowspan="1">41,290 (6.36)</td><td align="left" colspan="1" rowspan="1">280,786</td><td align="left" colspan="1" rowspan="1">1114</td><td align="left" colspan="1" rowspan="1">3.97</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">137,741</td><td align="left" colspan="1" rowspan="1">63,632 (46.20)</td><td align="left" colspan="1" rowspan="1">72,393 (52.56)</td><td align="left" colspan="1" rowspan="1">11,177 (8.11)</td><td align="left" colspan="1" rowspan="1">18,166 (13.19)</td><td align="left" colspan="1" rowspan="1">45,117 (32.75)</td><td align="left" colspan="1" rowspan="1">49,898 (36.23)</td><td align="left" colspan="1" rowspan="1">7738 (5.62)</td><td align="left" colspan="1" rowspan="1">63,243</td><td align="left" colspan="1" rowspan="1">384</td><td align="left" colspan="1" rowspan="1">6.07</td></tr><tr><td align="left" rowspan="10" colspan="1"><bold>Neurodevelopmental disorders</bold></td><td align="left" rowspan="2" colspan="1">France IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">367,279</td><td align="left" colspan="1" rowspan="1">157,233 (42.81)</td><td align="left" colspan="1" rowspan="1">205,574 (55.97)</td><td align="left" colspan="1" rowspan="1">33,106 (9.01)</td><td align="left" colspan="1" rowspan="1">30,873 (8.41)</td><td align="left" colspan="1" rowspan="1">107,624 (29.30)</td><td align="left" colspan="1" rowspan="1">125,034 (34.04)</td><td align="left" colspan="1" rowspan="1">60,188 (16.39)</td><td align="left" colspan="1" rowspan="1">161,542</td><td align="left" colspan="1" rowspan="1">215</td><td align="left" colspan="1" rowspan="1">1.33</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">53,581</td><td align="left" colspan="1" rowspan="1">22,535 (42.06)</td><td align="left" colspan="1" rowspan="1">30,317 (56.58)</td><td align="left" colspan="1" rowspan="1">4453 (8.31)</td><td align="left" colspan="1" rowspan="1">4219 (7.87)</td><td align="left" colspan="1" rowspan="1">15,938 (29.75)</td><td align="left" colspan="1" rowspan="1">18,559 (34.64)</td><td align="left" colspan="1" rowspan="1">7525 (14.04)</td><td align="left" colspan="1" rowspan="1">24,523</td><td align="left" colspan="1" rowspan="1">75</td><td align="left" colspan="1" rowspan="1">3.06</td></tr><tr><td align="left" rowspan="2" colspan="1">Germany IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">130,731</td><td align="left" colspan="1" rowspan="1">58,345 (44.63)</td><td align="left" colspan="1" rowspan="1">70,193 (53.69)</td><td align="left" colspan="1" rowspan="1">12,802 (9.79)</td><td align="left" colspan="1" rowspan="1">11,684 (8.94)</td><td align="left" colspan="1" rowspan="1">35,627 (27.25)</td><td align="left" colspan="1" rowspan="1">41,574 (31.80)</td><td align="left" colspan="1" rowspan="1">22,126 (16.92)</td><td align="left" colspan="1" rowspan="1">58,330</td><td align="left" colspan="1" rowspan="1">643</td><td align="left" colspan="1" rowspan="1">11.02</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">19,181</td><td align="left" colspan="1" rowspan="1">8754 (45.64)</td><td align="left" colspan="1" rowspan="1">10,340 (53.91)</td><td align="left" colspan="1" rowspan="1">1578 (8.23)</td><td align="left" colspan="1" rowspan="1">1775 (9.25)</td><td align="left" colspan="1" rowspan="1">5807 (30.27)</td><td align="left" colspan="1" rowspan="1">6740 (35.14)</td><td align="left" colspan="1" rowspan="1">2914 (15.19)</td><td align="left" colspan="1" rowspan="1">9003</td><td align="left" colspan="1" rowspan="1">68</td><td align="left" colspan="1" rowspan="1">7.55</td></tr><tr><td align="left" rowspan="2" colspan="1">Italy IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">49,087</td><td align="left" colspan="1" rowspan="1">18,733 (38.16)</td><td align="left" colspan="1" rowspan="1">25,918 (52.80)</td><td align="left" colspan="1" rowspan="1">1176 (2.40)</td><td align="left" colspan="1" rowspan="1">2950 (6.01)</td><td align="left" colspan="1" rowspan="1">12,134 (24.72)</td><td align="left" colspan="1" rowspan="1">19,697 (40.13)</td><td align="left" colspan="1" rowspan="1">13,068 (26.62)</td><td align="left" colspan="1" rowspan="1">22,325</td><td align="left" colspan="1" rowspan="1">22</td><td align="left" colspan="1" rowspan="1">0.99</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">8424</td><td align="left" colspan="1" rowspan="1">3195 (37.93)</td><td align="left" colspan="1" rowspan="1">4337 (51.48)</td><td align="left" colspan="1" rowspan="1">405 (4.81)</td><td align="left" colspan="1" rowspan="1">483 (5.73)</td><td align="left" colspan="1" rowspan="1">2040 (24.22)</td><td align="left" colspan="1" rowspan="1">3443 (40.87)</td><td align="left" colspan="1" rowspan="1">2001 (23.75)</td><td align="left" colspan="1" rowspan="1">3786</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">1.58</td></tr><tr><td align="left" rowspan="2" colspan="1">UK IMRD</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">310,702</td><td align="left" colspan="1" rowspan="1">133,535 (42.98)</td><td align="left" colspan="1" rowspan="1">175,062 (56.34)</td><td align="left" colspan="1" rowspan="1">35,124 (11.30)</td><td align="left" colspan="1" rowspan="1">31,317 (10.08)</td><td align="left" colspan="1" rowspan="1">97,332 (31.33)</td><td align="left" colspan="1" rowspan="1">96,350 (31.01)</td><td align="left" colspan="1" rowspan="1">42,682 (13.74)</td><td align="left" colspan="1" rowspan="1">136,903</td><td align="left" colspan="1" rowspan="1">384</td><td align="left" colspan="1" rowspan="1">2.8</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">35,694</td><td align="left" colspan="1" rowspan="1">15,447 (43.28)</td><td align="left" colspan="1" rowspan="1">20,221 (56.65)</td><td align="left" colspan="1" rowspan="1">3813 (10.68)</td><td align="left" colspan="1" rowspan="1">3689 (10.34)</td><td align="left" colspan="1" rowspan="1">11,114 (31.14)</td><td align="left" colspan="1" rowspan="1">11,212 (31.41)</td><td align="left" colspan="1" rowspan="1">5754 (16.12)</td><td align="left" colspan="1" rowspan="1">16,352</td><td align="left" colspan="1" rowspan="1">34</td><td align="left" colspan="1" rowspan="1">2.08</td></tr><tr><td align="left" rowspan="2" colspan="1">US PharMetrics Plus</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">630,465</td><td align="left" colspan="1" rowspan="1">287,575 (45.61)</td><td align="left" colspan="1" rowspan="1">336,474 (53.37)</td><td align="left" colspan="1" rowspan="1">62,324 (9.89)</td><td align="left" colspan="1" rowspan="1">75,937 (12.04)</td><td align="left" colspan="1" rowspan="1">201,789 (32.01)</td><td align="left" colspan="1" rowspan="1">224,114 (35.55)</td><td align="left" colspan="1" rowspan="1">45,506 (7.22)</td><td align="left" colspan="1" rowspan="1">271,166</td><td align="left" colspan="1" rowspan="1">4825</td><td align="left" colspan="1" rowspan="1">17.79</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">133,869</td><td align="left" colspan="1" rowspan="1">61,653 (46.05)</td><td align="left" colspan="1" rowspan="1">70,521 (52.68)</td><td align="left" colspan="1" rowspan="1">10,254 (7.66)</td><td align="left" colspan="1" rowspan="1">16,960 (12.67)</td><td align="left" colspan="1" rowspan="1">43,330 (32.37)</td><td align="left" colspan="1" rowspan="1">49,097 (36.68)</td><td align="left" colspan="1" rowspan="1">8751 (6.54)</td><td align="left" colspan="1" rowspan="1">61,137</td><td align="left" colspan="1" rowspan="1">1129</td><td align="left" colspan="1" rowspan="1">18.47</td></tr><tr><td align="left" rowspan="10" colspan="1"><bold>Overall</bold></td><td align="left" rowspan="2" colspan="1">France IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">304,558</td><td align="left" colspan="1" rowspan="1">136,940 (44.96)</td><td align="left" colspan="1" rowspan="1">164,901 (54.14)</td><td align="left" colspan="1" rowspan="1">32,186 (10.57)</td><td align="left" colspan="1" rowspan="1">28,370 (9.32)</td><td align="left" colspan="1" rowspan="1">91,590 (30.07)</td><td align="left" colspan="1" rowspan="1">99,294 (32.60)</td><td align="left" colspan="1" rowspan="1">45,660 (14.99)</td><td align="left" colspan="1" rowspan="1">130,911</td><td align="left" colspan="1" rowspan="1">11,413</td><td align="left" colspan="1" rowspan="1">87.18</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">44,390</td><td align="left" colspan="1" rowspan="1">19,614 (44.19)</td><td align="left" colspan="1" rowspan="1">24,173 (54.46)</td><td align="left" colspan="1" rowspan="1">4318 (9.73)</td><td align="left" colspan="1" rowspan="1">3873 (8.72)</td><td align="left" colspan="1" rowspan="1">13,393 (30.17)</td><td align="left" colspan="1" rowspan="1">14,600 (32.89)</td><td align="left" colspan="1" rowspan="1">5685 (12.81)</td><td align="left" colspan="1" rowspan="1">19,394</td><td align="left" colspan="1" rowspan="1">2909</td><td align="left" colspan="1" rowspan="1">149.99</td></tr><tr><td align="left" rowspan="2" colspan="1">Germany IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">111,888</td><td align="left" colspan="1" rowspan="1">51,093 (45.66)</td><td align="left" colspan="1" rowspan="1">58,863 (52.61)</td><td align="left" colspan="1" rowspan="1">12,460 (11.14)</td><td align="left" colspan="1" rowspan="1">10,633 (9.50)</td><td align="left" colspan="1" rowspan="1">31,121 (27.81)</td><td align="left" colspan="1" rowspan="1">35,003 (31.28)</td><td align="left" colspan="1" rowspan="1">17,060 (15.25)</td><td align="left" colspan="1" rowspan="1">48,094</td><td align="left" colspan="1" rowspan="1">6674</td><td align="left" colspan="1" rowspan="1">138.77</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">16,528</td><td align="left" colspan="1" rowspan="1">7752 (46.90)</td><td align="left" colspan="1" rowspan="1">8708 (52.69)</td><td align="left" colspan="1" rowspan="1">1527 (9.24)</td><td align="left" colspan="1" rowspan="1">1618 (9.79)</td><td align="left" colspan="1" rowspan="1">5059 (30.61)</td><td align="left" colspan="1" rowspan="1">5754 (34.81)</td><td align="left" colspan="1" rowspan="1">2277 (13.78)</td><td align="left" colspan="1" rowspan="1">7408</td><td align="left" colspan="1" rowspan="1">1233</td><td align="left" colspan="1" rowspan="1">166.43</td></tr><tr><td align="left" rowspan="2" colspan="1">Italy IQVIA</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">42,485</td><td align="left" colspan="1" rowspan="1">16,783 (39.50)</td><td align="left" colspan="1" rowspan="1">21,786 (51.28)</td><td align="left" colspan="1" rowspan="1">1044 (2.46)</td><td align="left" colspan="1" rowspan="1">2873 (6.76)</td><td align="left" colspan="1" rowspan="1">11,293 (26.58)</td><td align="left" colspan="1" rowspan="1">17,334 (40.80)</td><td align="left" colspan="1" rowspan="1">9876 (23.25)</td><td align="left" colspan="1" rowspan="1">19,103</td><td align="left" colspan="1" rowspan="1">995</td><td align="left" colspan="1" rowspan="1">52.09</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">7252</td><td align="left" colspan="1" rowspan="1">2864 (39.49)</td><td align="left" colspan="1" rowspan="1">3630 (50.06)</td><td align="left" colspan="1" rowspan="1">356 (4.91)</td><td align="left" colspan="1" rowspan="1">472 (6.51)</td><td align="left" colspan="1" rowspan="1">1889 (26.05)</td><td align="left" colspan="1" rowspan="1">2991 (41.24)</td><td align="left" colspan="1" rowspan="1">1509 (20.81)</td><td align="left" colspan="1" rowspan="1">3167</td><td align="left" colspan="1" rowspan="1">325</td><td align="left" colspan="1" rowspan="1">102.59</td></tr><tr><td align="left" rowspan="2" colspan="1">UK IMRD</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">296,306</td><td align="left" colspan="1" rowspan="1">128,703 (43.44)</td><td align="left" colspan="1" rowspan="1">165,704 (55.92)</td><td align="left" colspan="1" rowspan="1">34,785 (11.74)</td><td align="left" colspan="1" rowspan="1">29,970 (10.11)</td><td align="left" colspan="1" rowspan="1">92,966 (31.37)</td><td align="left" colspan="1" rowspan="1">93,187 (31.45)</td><td align="left" colspan="1" rowspan="1">38,332 (12.94)</td><td align="left" colspan="1" rowspan="1">130,123</td><td align="left" colspan="1" rowspan="1">4210</td><td align="left" colspan="1" rowspan="1">32.35</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">33,989</td><td align="left" colspan="1" rowspan="1">14,851 (43.69)</td><td align="left" colspan="1" rowspan="1">19,108 (56.22)</td><td align="left" colspan="1" rowspan="1">3775 (11.11)</td><td align="left" colspan="1" rowspan="1">3526 (10.37)</td><td align="left" colspan="1" rowspan="1">10,618 (31.24)</td><td align="left" colspan="1" rowspan="1">10,867 (31.97)</td><td align="left" colspan="1" rowspan="1">5094 (14.99)</td><td align="left" colspan="1" rowspan="1">15,500</td><td align="left" colspan="1" rowspan="1">631</td><td align="left" colspan="1" rowspan="1">40.71</td></tr><tr><td align="left" rowspan="2" colspan="1">US PharMetrics Plus</td><td align="left" colspan="1" rowspan="1">Comparators</td><td align="left" colspan="1" rowspan="1">453,727</td><td align="left" colspan="1" rowspan="1">218,987 (48.26)</td><td align="left" colspan="1" rowspan="1">230,194 (50.73)</td><td align="left" colspan="1" rowspan="1">56,371 (12.42)</td><td align="left" colspan="1" rowspan="1">58,638 (12.92)</td><td align="left" colspan="1" rowspan="1">146,413 (32.27)</td><td align="left" colspan="1" rowspan="1">152,990 (33.72)</td><td align="left" colspan="1" rowspan="1">25,942 (5.72)</td><td align="left" colspan="1" rowspan="1">188,242</td><td align="left" colspan="1" rowspan="1">36,020</td><td align="left" colspan="1" rowspan="1">191.35</td></tr><tr><td align="left" colspan="1" rowspan="1">Targets</td><td align="left" colspan="1" rowspan="1">98,366</td><td align="left" colspan="1" rowspan="1">48,070 (48.87)</td><td align="left" colspan="1" rowspan="1">48,919 (49.73)</td><td align="left" colspan="1" rowspan="1">9265 (9.42)</td><td align="left" colspan="1" rowspan="1">13,538 (13.76)</td><td align="left" colspan="1" rowspan="1">32,248 (32.78)</td><td align="left" colspan="1" rowspan="1">34,156 (34.72)</td><td align="left" colspan="1" rowspan="1">4866 (4.95)</td><td align="left" colspan="1" rowspan="1">42,281</td><td align="left" colspan="1" rowspan="1">10,292</td><td align="left" colspan="1" rowspan="1">243.41</td></tr></tbody></table></table-wrap></p><p id="Par26">The short-term (6&#160;months) incidence rate was generally high for anxiety disorders, depression, and sleep disorders. The highest incidence of 130.16 per 1000 person-years was observed among individuals with COVID-19 for anxiety disorders in the USA, followed by 85.5 per 1000 person-years for anxiety disorders in France and 84.87 per 1000 person-years for sleep disorders in the USA. No self-harm and suicide cases were observed in Germany and Italy. Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Tables S4&#8211;S5 show the sample size, sex and age distribution, follow-up time, and number and incidence of psychiatric and neuropsychiatric events for the medium- and long-term observation periods. The incidence of outcomes in the medium- and long-term observation periods was lower than the short-term results. The incidence of any outcome among individuals with COVID-19 for the short-, medium-, and long-term periods&#160;ranged from 40.71, 28.73, and 27.67 per 1000 person-years in the UK, to 243.41, 144.11, and 119.95 per 1000 person-years in the USA, respectively.</p><p id="Par27">Table <xref rid="Tab2" ref-type="table">2</xref> shows selected baseline characteristics before and after propensity score matching for France IQVIA, using short-term depression risk as an example. Before propensity score matching, individuals with COVID-19 were more likely to have acute respiratory disease and use antibacterial, anti-inflammatory, antirheumatic, and opioid products, with standardized difference of mean up to 0.77. After propensity score matching, all standardized differences were less than 0.2, and most were less than 0.1, indicating that the samples of individuals with and without COVID-19 were well-balanced after matching. Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Tables S6.1&#8211;S6.179 show the baseline characteristics for all outcomes in all databases, which had similar results.
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Selected baseline characteristics for France IQVIA, using short-term depression risk as an example</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Characteristic</th><th align="left" colspan="3" rowspan="1">Before propensity score matching</th><th align="left" colspan="3" rowspan="1">After propensity score matching</th></tr><tr><th align="left" colspan="1" rowspan="1"><bold>Targets, %</bold></th><th align="left" colspan="1" rowspan="1"><bold>Comparators, %</bold></th><th align="left" colspan="1" rowspan="1"><bold>Standardized difference</bold></th><th align="left" colspan="1" rowspan="1"><bold>Targets, %</bold></th><th align="left" colspan="1" rowspan="1"><bold>Comparators, %</bold></th><th align="left" colspan="1" rowspan="1"><bold>Standardized difference</bold></th></tr></thead><tbody><tr><td align="left" colspan="7" rowspan="1"><bold>Age group</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;0&#8211;4</td><td align="left" colspan="1" rowspan="1">0.7</td><td align="left" colspan="1" rowspan="1">2.9</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.17</td><td align="left" colspan="1" rowspan="1">0.8</td><td align="left" colspan="1" rowspan="1">1.2</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.04</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;5&#8211;9</td><td align="left" colspan="1" rowspan="1">1.8</td><td align="left" colspan="1" rowspan="1">4.4</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.15</td><td align="left" colspan="1" rowspan="1">1.9</td><td align="left" colspan="1" rowspan="1">2.3</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.03</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;10&#8211;14</td><td align="left" colspan="1" rowspan="1">3.2</td><td align="left" colspan="1" rowspan="1">4.4</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.06</td><td align="left" colspan="1" rowspan="1">3.4</td><td align="left" colspan="1" rowspan="1">3.7</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;15&#8211;19</td><td align="left" colspan="1" rowspan="1">5.6</td><td align="left" colspan="1" rowspan="1">4.3</td><td align="left" colspan="1" rowspan="1">0.06</td><td align="left" colspan="1" rowspan="1">5.6</td><td align="left" colspan="1" rowspan="1">5.9</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;20&#8211;24</td><td align="left" colspan="1" rowspan="1">7.3</td><td align="left" colspan="1" rowspan="1">4.2</td><td align="left" colspan="1" rowspan="1">0.13</td><td align="left" colspan="1" rowspan="1">7.1</td><td align="left" colspan="1" rowspan="1">6.5</td><td align="left" colspan="1" rowspan="1">0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;25&#8211;29</td><td align="left" colspan="1" rowspan="1">7.3</td><td align="left" colspan="1" rowspan="1">4.3</td><td align="left" colspan="1" rowspan="1">0.13</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">6.7</td><td align="left" colspan="1" rowspan="1">0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;30&#8211;34</td><td align="left" colspan="1" rowspan="1">8.3</td><td align="left" colspan="1" rowspan="1">5.1</td><td align="left" colspan="1" rowspan="1">0.13</td><td align="left" colspan="1" rowspan="1">8.1</td><td align="left" colspan="1" rowspan="1">7.7</td><td align="left" colspan="1" rowspan="1">0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;35&#8211;39</td><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">5.6</td><td align="left" colspan="1" rowspan="1">0.13</td><td align="left" colspan="1" rowspan="1">8.6</td><td align="left" colspan="1" rowspan="1">7.9</td><td align="left" colspan="1" rowspan="1">0.03</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;40&#8211;44</td><td align="left" colspan="1" rowspan="1">9.4</td><td align="left" colspan="1" rowspan="1">5.9</td><td align="left" colspan="1" rowspan="1">0.13</td><td align="left" colspan="1" rowspan="1">9.1</td><td align="left" colspan="1" rowspan="1">8.3</td><td align="left" colspan="1" rowspan="1">0.03</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;45&#8211;49</td><td align="left" colspan="1" rowspan="1">10.1</td><td align="left" colspan="1" rowspan="1">6.8</td><td align="left" colspan="1" rowspan="1">0.12</td><td align="left" colspan="1" rowspan="1">9.9</td><td align="left" colspan="1" rowspan="1">9.2</td><td align="left" colspan="1" rowspan="1">0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;50&#8211;54</td><td align="left" colspan="1" rowspan="1">9.8</td><td align="left" colspan="1" rowspan="1">7.5</td><td align="left" colspan="1" rowspan="1">0.08</td><td align="left" colspan="1" rowspan="1">9.6</td><td align="left" colspan="1" rowspan="1">9.4</td><td align="left" colspan="1" rowspan="1">0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;55&#8211;59</td><td align="left" colspan="1" rowspan="1">8.9</td><td align="left" colspan="1" rowspan="1">7.8</td><td align="left" colspan="1" rowspan="1">0.04</td><td align="left" colspan="1" rowspan="1">8.9</td><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;65&#8211;69</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">7.7</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.16</td><td align="left" colspan="1" rowspan="1">4.3</td><td align="left" colspan="1" rowspan="1">4.7</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;70&#8211;74</td><td align="left" colspan="1" rowspan="1">3.7</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.19</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">4.6</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.03</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;75&#8211;79</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">5.2</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.17</td><td align="left" colspan="1" rowspan="1">2.2</td><td align="left" colspan="1" rowspan="1">2.7</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.03</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;80&#8211;84</td><td align="left" colspan="1" rowspan="1">1.3</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.17</td><td align="left" colspan="1" rowspan="1">1.5</td><td align="left" colspan="1" rowspan="1">1.8</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;85&#8211;89</td><td align="left" colspan="1" rowspan="1">0.9</td><td align="left" colspan="1" rowspan="1">2.6</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.13</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">1.3</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.03</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;90&#8211;94</td><td align="left" colspan="1" rowspan="1">0.4</td><td align="left" colspan="1" rowspan="1">1.1</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.08</td><td align="left" colspan="1" rowspan="1">0.4</td><td align="left" colspan="1" rowspan="1">0.6</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.03</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;95&#8211;99</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.03</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.01</td></tr><tr><td align="left" colspan="7" rowspan="1"><bold>Sex</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Female</td><td align="left" colspan="1" rowspan="1">56.4</td><td align="left" colspan="1" rowspan="1">57.4</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.02</td><td align="left" colspan="1" rowspan="1">55.9</td><td align="left" colspan="1" rowspan="1">55</td><td align="left" colspan="1" rowspan="1">0.02</td></tr><tr><td align="left" colspan="7" rowspan="1"><bold>Medical history: general</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Acute respiratory disease</td><td align="left" colspan="1" rowspan="1">16.7</td><td align="left" colspan="1" rowspan="1">6.9</td><td align="left" colspan="1" rowspan="1">0.31</td><td align="left" colspan="1" rowspan="1">15.7</td><td align="left" colspan="1" rowspan="1">18.7</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.08</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Chronic liver disease</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0.01</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Chronic obstructive lung disease</td><td align="left" colspan="1" rowspan="1">0.9</td><td align="left" colspan="1" rowspan="1">0.7</td><td align="left" colspan="1" rowspan="1">0.02</td><td align="left" colspan="1" rowspan="1">0.9</td><td align="left" colspan="1" rowspan="1">1.3</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.04</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Crohn&#8217;s disease</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0.01</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Dementia</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Depressive disorder</td><td align="left" colspan="1" rowspan="1">6.1</td><td align="left" colspan="1" rowspan="1">3.2</td><td align="left" colspan="1" rowspan="1">0.14</td><td align="left" colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0.04</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Diabetes mellitus</td><td align="left" colspan="1" rowspan="1">5.2</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">0.06</td><td align="left" colspan="1" rowspan="1">5.4</td><td align="left" colspan="1" rowspan="1">6.8</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.06</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Gastroesophageal reflux disease</td><td align="left" colspan="1" rowspan="1">4.3</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">0.13</td><td align="left" colspan="1" rowspan="1">4.2</td><td align="left" colspan="1" rowspan="1">5.4</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.06</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Gastrointestinal hemorrhage</td><td align="left" colspan="1" rowspan="1">0.5</td><td align="left" colspan="1" rowspan="1">0.3</td><td align="left" colspan="1" rowspan="1">0.04</td><td align="left" colspan="1" rowspan="1">0.4</td><td align="left" colspan="1" rowspan="1">0.6</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Human immunodeficiency virus infection</td><td align="left" colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0.03</td><td align="left" colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1">0.4</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.04</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hyperlipidemia</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">0.06</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">4.8</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.04</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hypertensive disorder</td><td align="left" colspan="1" rowspan="1">11.7</td><td align="left" colspan="1" rowspan="1">9.9</td><td align="left" colspan="1" rowspan="1">0.06</td><td align="left" colspan="1" rowspan="1">12.1</td><td align="left" colspan="1" rowspan="1">15.6</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Lesion of liver</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Obesity</td><td align="left" colspan="1" rowspan="1">0.4</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0.05</td><td align="left" colspan="1" rowspan="1">0.3</td><td align="left" colspan="1" rowspan="1">0.3</td><td align="left" colspan="1" rowspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Osteoarthritis</td><td align="left" colspan="1" rowspan="1">3.8</td><td align="left" colspan="1" rowspan="1">2.2</td><td align="left" colspan="1" rowspan="1">0.09</td><td align="left" colspan="1" rowspan="1">3.6</td><td align="left" colspan="1" rowspan="1">4.5</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.05</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Pneumonia</td><td align="left" colspan="1" rowspan="1">0.8</td><td align="left" colspan="1" rowspan="1">0.3</td><td align="left" colspan="1" rowspan="1">0.07</td><td align="left" colspan="1" rowspan="1">0.7</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.03</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Psoriasis</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">0.5</td><td align="left" colspan="1" rowspan="1">0.05</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">1.1</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Renal impairment</td><td align="left" colspan="1" rowspan="1">0.3</td><td align="left" colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1">0.02</td><td align="left" colspan="1" rowspan="1">0.3</td><td align="left" colspan="1" rowspan="1">0.4</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Rheumatoid arthritis</td><td align="left" colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1">0.3</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.01</td><td align="left" colspan="1" rowspan="1">0.3</td><td align="left" colspan="1" rowspan="1">0.3</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Schizophrenia</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Ulcerative colitis</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0.01</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Urinary tract infectious disease</td><td align="left" colspan="1" rowspan="1">1.5</td><td align="left" colspan="1" rowspan="1">0.7</td><td align="left" colspan="1" rowspan="1">0.07</td><td align="left" colspan="1" rowspan="1">1.4</td><td align="left" colspan="1" rowspan="1">1.9</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.03</td></tr><tr><td align="left" colspan="7" rowspan="1"><bold>Medical history (cardiovascular disease)</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Atrial fibrillation</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0.3</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.03</td><td align="left" colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Cerebrovascular disease</td><td align="left" colspan="1" rowspan="1">0.9</td><td align="left" colspan="1" rowspan="1">0.8</td><td align="left" colspan="1" rowspan="1">0.02</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">1.4</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.04</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Coronary arteriosclerosis</td><td align="left" colspan="1" rowspan="1">0.4</td><td align="left" colspan="1" rowspan="1">0.4</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0.4</td><td align="left" colspan="1" rowspan="1">0.6</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.03</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Heart disease</td><td align="left" colspan="1" rowspan="1">3.3</td><td align="left" colspan="1" rowspan="1">3.6</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.02</td><td align="left" colspan="1" rowspan="1">3.4</td><td align="left" colspan="1" rowspan="1">4.7</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.07</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Heart failure</td><td align="left" colspan="1" rowspan="1">0.3</td><td align="left" colspan="1" rowspan="1">0.3</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.01</td><td align="left" colspan="1" rowspan="1">0.3</td><td align="left" colspan="1" rowspan="1">0.4</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Ischemic heart disease</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">0.9</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">1.1</td><td align="left" colspan="1" rowspan="1">1.5</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.03</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Peripheral vascular disease</td><td align="left" colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1">0.4</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.03</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Medical history (neoplasms)</bold></td><td align="left" colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0.01</td><td align="left" colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1">0.3</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Venous thrombosis</td><td align="left" colspan="1" rowspan="1">0.3</td><td align="left" colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1">0.03</td><td align="left" colspan="1" rowspan="1">0.3</td><td align="left" colspan="1" rowspan="1">0.4</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Medical history: Neoplasms</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Malignant neoplastic disease</td><td align="left" colspan="1" rowspan="1">1.1</td><td align="left" colspan="1" rowspan="1">0.8</td><td align="left" colspan="1" rowspan="1">0.03</td><td align="left" colspan="1" rowspan="1">1.2</td><td align="left" colspan="1" rowspan="1">1.7</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.04</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Malignant tumor of breast</td><td align="left" colspan="1" rowspan="1">0.3</td><td align="left" colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1">0.02</td><td align="left" colspan="1" rowspan="1">0.3</td><td align="left" colspan="1" rowspan="1">0.4</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Malignant tumor of colon</td><td align="left" colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0.03</td><td align="left" colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Primary malignant neoplasm of prostate</td><td align="left" colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0.01</td><td align="left" colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1">0.3</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.03</td></tr><tr><td align="left" colspan="7" rowspan="1"><bold>Medication use</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Agents acting on the renin-angiotensin system</td><td align="left" colspan="1" rowspan="1">10.5</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">0.02</td><td align="left" colspan="1" rowspan="1">11.1</td><td align="left" colspan="1" rowspan="1">14.2</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.09</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Antibacterials for systemic use</td><td align="left" colspan="1" rowspan="1">36.9</td><td align="left" colspan="1" rowspan="1">16.7</td><td align="left" colspan="1" rowspan="1">0.47</td><td align="left" colspan="1" rowspan="1">34.7</td><td align="left" colspan="1" rowspan="1">39.4</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Antidepressants</td><td align="left" colspan="1" rowspan="1">7.3</td><td align="left" colspan="1" rowspan="1">4.7</td><td align="left" colspan="1" rowspan="1">0.11</td><td align="left" colspan="1" rowspan="1">3.5</td><td align="left" colspan="1" rowspan="1">4.3</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.04</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Antiepileptics</td><td align="left" colspan="1" rowspan="1">2.4</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">0.03</td><td align="left" colspan="1" rowspan="1">2.2</td><td align="left" colspan="1" rowspan="1">3.3</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.06</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Antiinflammatory and antirheumatic products</td><td align="left" colspan="1" rowspan="1">35.2</td><td align="left" colspan="1" rowspan="1">20.3</td><td align="left" colspan="1" rowspan="1">0.34</td><td align="left" colspan="1" rowspan="1">35.3</td><td align="left" colspan="1" rowspan="1">40.1</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Antineoplastic agents</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">0.8</td><td align="left" colspan="1" rowspan="1">0.02</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">1.2</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Antipsoriatics</td><td align="left" colspan="1" rowspan="1">0.5</td><td align="left" colspan="1" rowspan="1">0.3</td><td align="left" colspan="1" rowspan="1">0.03</td><td align="left" colspan="1" rowspan="1">0.5</td><td align="left" colspan="1" rowspan="1">0.7</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Antithrombotic agents</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">7.6</td><td align="left" colspan="1" rowspan="1">0.01</td><td align="left" colspan="1" rowspan="1">8.3</td><td align="left" colspan="1" rowspan="1">10.6</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.08</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Beta blocking agents</td><td align="left" colspan="1" rowspan="1">6.3</td><td align="left" colspan="1" rowspan="1">6.4</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">6.5</td><td align="left" colspan="1" rowspan="1">8.1</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.06</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Calcium channel blockers</td><td align="left" colspan="1" rowspan="1">5.8</td><td align="left" colspan="1" rowspan="1">5.3</td><td align="left" colspan="1" rowspan="1">0.02</td><td align="left" colspan="1" rowspan="1">6.1</td><td align="left" colspan="1" rowspan="1">7.9</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.07</td></tr><tr><td align="left" colspan="7" rowspan="1"><bold>Medication use</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Diuretics</td><td align="left" colspan="1" rowspan="1">5.3</td><td align="left" colspan="1" rowspan="1">5.5</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.01</td><td align="left" colspan="1" rowspan="1">5.6</td><td align="left" colspan="1" rowspan="1">7.4</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.07</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Drugs for acid-related disorders</td><td align="left" colspan="1" rowspan="1">24.5</td><td align="left" colspan="1" rowspan="1">14.2</td><td align="left" colspan="1" rowspan="1">0.26</td><td align="left" colspan="1" rowspan="1">24.1</td><td align="left" colspan="1" rowspan="1">28.2</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.09</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Drugs for obstructive airway diseases</td><td align="left" colspan="1" rowspan="1">23.1</td><td align="left" colspan="1" rowspan="1">12.6</td><td align="left" colspan="1" rowspan="1">0.28</td><td align="left" colspan="1" rowspan="1">22.7</td><td align="left" colspan="1" rowspan="1">26.8</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.09</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Drugs used in diabetes</td><td align="left" colspan="1" rowspan="1">5.5</td><td align="left" colspan="1" rowspan="1">4.3</td><td align="left" colspan="1" rowspan="1">0.05</td><td align="left" colspan="1" rowspan="1">5.7</td><td align="left" colspan="1" rowspan="1">7.2</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.06</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Immunosuppressants</td><td align="left" colspan="1" rowspan="1">0.3</td><td align="left" colspan="1" rowspan="1">0.5</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.03</td><td align="left" colspan="1" rowspan="1">0.3</td><td align="left" colspan="1" rowspan="1">0.4</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Opioids</td><td align="left" colspan="1" rowspan="1">58.5</td><td align="left" colspan="1" rowspan="1">23.4</td><td align="left" colspan="1" rowspan="1">0.77</td><td align="left" colspan="1" rowspan="1">56.1</td><td align="left" colspan="1" rowspan="1">57.9</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.04</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Psycholeptics</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">8.7</td><td align="left" colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1">12.6</td><td align="left" colspan="1" rowspan="1">15.2</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.07</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Psychostimulants, agents used for ADHD and nootropics</td><td align="left" colspan="1" rowspan="1">4.5</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">0.14</td><td align="left" colspan="1" rowspan="1">4.2</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">&#8201;&#8722;&#8201;0.03</td></tr></tbody></table></table-wrap></p><p id="Par28">Figure&#160;<xref rid="Fig1" ref-type="fig">1</xref> and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S7 show the short-term risks of psychiatric and neuropsychiatric outcomes. During the first 6&#160;months following the index date, individuals with COVID-19 had a significantly higher risk of developing any psychiatric and neuropsychiatric disorder than individuals without COVID-19 across all databases. The HRs ranged from 1.14 (95% CI, 1.07&#8211;1.22) in Germany to 1.89 (1.64&#8211;2.17) in Italy. Specifically, the risk of depression was higher in individuals with COVID-19 in all databases except for the UK, with HRs ranging from 1.05 (1.01&#8211;1.09) in the USA to 1.90 in Italy (1.55&#8211;2.31). Significant HRs for anxiety disorders were found in all databases except for Germany, ranging from 1.18 (1.14&#8211;1.21) in the USA to 2.43 (1.61&#8211;3.61) in Italy. An increased risk of psychoses was observed in Italy (HR 2.39, 95% CI 1.09&#8211;4.85) and the USA (1.41, 1.17&#8211;1.70). Increased risks of substance misuse or dependence and personality disorders were found among individuals with COVID-19 in the USA (1.14, 1.08&#8211;1.19) and Italy (1.55, 1.04&#8211;2.25), respectively. Additionally, COVID-19 was associated with an elevated risk of sleep disorders in France (1.34, 1.25&#8211;1.44), Italy (1.73, 1.39&#8211;2.14), and the USA (1.21, 1.16&#8211;1.25). Individuals with COVID-19 had an increased risk of dementia in the UK (1.86, 1.50&#8211;2.28), France (1.84, 1.12-2.91), and the USA (1.43, 1.26&#8211;1.63). A significant HR for neurodevelopmental disorders was observed only in France (2.20, 1.65&#8211;2.91).<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Risk of developing outcome events among individuals with COVID-19 in the short-term observation period (within 6&#160;months)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="12916_2025_3952_Fig1_HTML.jpg"/></fig></p><p id="Par29">No significant associations were observed between COVID-19 and any of the psychiatric and neuropsychiatric disorders in the medium-term (6&#160;months to 1&#160;year) or long-term (1 to 2&#160;years) periods, except for France (medium-term: HR 1.26, 95% CI 1.19&#8211;1.34; long-term: 1.34, 1.27&#8211;1.41) (see Figs. <xref rid="Fig2" ref-type="fig">2</xref> and <xref rid="Fig3" ref-type="fig">3</xref> and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S7). In France IQVIA, individuals with COVID-19 had a higher risk of depression (HR 1.29, 95% CI 1.18&#8211;1.41), anxiety disorders (1.29, 1.20&#8211;1.38), and sleep disorders (1.10, 1.01&#8211;1.21) during the medium-term observation, compared to matched comparators. Additionally, in the UK, an elevated risk of dementia (1.65, 1.28&#8211;2.10) was observed during the medium-term. In the long-term, elevated risks were only observed for depression (1.36, 1.25&#8211;1.47), anxiety disorders (1.37, 1.29&#8211;1.47), and sleep disorders (1.14, 1.05&#8211;1.24) in France.</p><p id="Par30">Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Tables S8&#8211;S14 show the results of subgroup analyses. The risk of psychiatric and neuropsychiatric disorders associated with COVID-19 varied by sex and age group. For example, in the UK, there was an increased short-term risk of anxiety disorders (HR 1.59, 95% CI 1.24&#8211;2.01) and bipolar disorders (5.15, 1.35&#8211;17.09) among males, but not females.<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Risk of developing outcome events among individuals with COVID-19 in the medium-term observation period (6&#160;months to 1&#160;year)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="12916_2025_3952_Fig2_HTML.jpg"/></fig><fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>Risk of developing outcome events among individuals with COVID-19 in the long-term observation period (1&#160;year to 2&#160;years)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="12916_2025_3952_Fig3_HTML.jpg"/></fig></p><p id="Par31">Additionally, a significantly higher short-term risk of substance misuse or dependence (HR&#160;1.26, 1.18&#8211;1.34) was observed only among males in the USA. In age group-stratified analyses for short-, medium-, and long-term risks, significant HRs for sleep disorders were only observed among individuals aged 25&#160;years or older in France, Italy, and the USA. An elevated risk of substance misuse or dependence was observed among individuals aged 18&#8211;44&#160;years and those aged 65&#160;years or older in Italy and the USA.</p></sec><sec id="Sec9"><title>Discussion</title><p id="Par32">In this multinational network study using population-based electronic medical records and claims data from four European countries and the USA, we compared the short-, medium-, and long-term risks of 11 psychiatric and neuropsychiatric disorders of individuals with and without COVID-19. During the first 6&#160;months post-infection, an overall increased risk of psychiatric and neuropsychiatric disorders was evident across all databases, with increased risks consistently observed in depression, anxiety disorders, and sleep disorders. Increased risks were only observed for depression, anxiety disorders, sleep disorders in France, and dementia in the UK, in the medium- and long-term observation periods.</p><p id="Par33">Previous studies have consistently demonstrated that a considerable number of individuals infected with COVID-19 suffer from mental and neurological health issues extending weeks to months beyond the acute phase of the illness. For instance, a meta-analysis of 51 studies involving approximately 19,000 subjects found that 27.4% of COVID-19 survivors experienced sleep disorders, 20.2% had cognitive impairment, 19.1% had anxiety disorders, and 12.9% had depression following the infection [<xref ref-type="bibr" rid="CR35">35</xref>]. Furthermore, studies from Denmark, Estonia, Iceland, Norway, Sweden, the UK, and the USA indicated an increased risk of psychiatric and neuropsychiatric sequelae in COVID-19 survivors compared to those uninfected by the virus or those suffering from influenza or other respiratory infections [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR14">14</xref>]. However, most of these studies had a follow-up period of less than 1&#160;year, thus not necessarily capturing the potential long-term consequences or accounting for the possibility of delayed help-seeking due to barriers in accessing mental health services. Additionally, the applicability of these findings may be limited by variations in how the index date is determined and the absence of standardized measurements or tools for identifying outcomes [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. By applying standardized definitions and analytical codes across five population-based databases, our study contributes multinational, large-scale evidence on the psychiatric and neuropsychiatric consequences associated with COVID-19 during a 2-year post-infection timeframe.</p><p id="Par34">Our study found that individuals with COVID-19 showed an increased likelihood of developing psychiatric and neuropsychiatric disorders within the 6&#160;months following infection, consistent with existing research on COVID [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR14">14</xref>], mirroring outcomes observed during past coronaviruses outbreaks [<xref ref-type="bibr" rid="CR8">8</xref>], and supporting the direct and indirect impact of COVID-19 on mental and neuropsychiatric health. While some studies have suggested that immune dysfunction, including nonspecific neuroinflammation and antineural autoimmune dysregulation, may be associated with the psychiatric and neuropsychiatric sequelae of SARS-CoV-2 during the acute phase of the disease [<xref ref-type="bibr" rid="CR38">38</xref>&#8211;<xref ref-type="bibr" rid="CR40">40</xref>], the pathophysiological mechanisms underlying these manifestations still remain poorly understood. Additionally, pandemic-related psychosocial stressors, such as unprecedented social isolation due to lockdowns and quarantine, financial insecurity from economic downturns, and grief over the loss of loved ones might have contributed to psychiatric symptoms, although the impact should be similar between individuals with and without COVID-19 [<xref ref-type="bibr" rid="CR41">41</xref>&#8211;<xref ref-type="bibr" rid="CR45">45</xref>]. It is worth noting that our study focused on individuals infected by the early strain of COVID-19 in 2020, a period associated with greater disease severity [<xref ref-type="bibr" rid="CR46">46</xref>]. The fear of illness, lack of vaccines, disrupted daily routines, and stigma associated with COVID-19 infection leading to social ostracization, further contributed to the psychological burden and heightened the risk of psychiatric manifestations among individuals with COVID-19 [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>].</p><p id="Par35">While our investigation revealed several psychiatric and neuropsychiatric sequelae of COVID-19 in the 6&#160;months following infection, significant differences in risk were observed only for depression, anxiety disorders and sleep disorders in France, and dementia in the UK during the medium- and long-term observation periods. This finding is partly consistent with a previous USA study, which reported that the risks of mood disorders, anxiety disorders, and insomnia associated with COVID-19 decreased 1 to 3&#160;months after the infection, while the risks of dementia and psychotic disorder remained elevated after 2&#160;years [<xref ref-type="bibr" rid="CR15">15</xref>]. The attenuation of risk can be attributed to several reasons. First, individuals with an incident diagnosis of psychiatric and neuropsychiatric disorder during the first 6&#160;months post-infection were excluded from the mid- and long-term analyses. Therefore, the risks after 6&#160;months might be lower if an individual already &#8220;survived&#8221; the acute phase of the pandemic. Second, physical status gradually recovers over time, which includes the alleviation of the virus&#8217;s direct neurological effects that may have initially led to such disorders [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. Third, as the pandemic progressed, individuals adapted to the psychosocial stressors triggered by the pandemic. People have found appropriate coping mechanisms and adjusted to changed circumstances, reducing the impact of these stressors on mental health [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. Fourth, as public health measures control the spread of the virus and vaccines become widely available, the initial fear and uncertainty surrounding COVID-19 and its consequences diminish. Additionally, the implementation of specialized mental health services for COVID-19 survivors helps address and mitigate the long-term psychiatric and neuropsychiatric effects of the virus. However, explaining the considerable heterogeneity in relative risks between countries remains challenging, as the mechanisms underlying the association between COVID-19 infection and psychiatric and neuropsychiatric outcomes are not yet fully understood [<xref ref-type="bibr" rid="CR38">38</xref>&#8211;<xref ref-type="bibr" rid="CR40">40</xref>]. The significant medium- and long-term increased risks observed in France and the UK may reflect the diverse impacts of differences in COVID-19 containment strategies, health systems, and rates of socioeconomic recovery by country, rather than the pandemic itself. Furthermore, the results may be partially influenced by detection bias, given the severe underdiagnosis and considerable diagnostic delays associated with psychiatric and neuropsychiatric disorders. For instance, the longer effect on dementia observed in the UK could simply result from longer waiting times for dementia assessments. Further research is required to explore the causes of this discrepancy to mitigate potential long-lasting impacts.</p><p id="Par36">Our study has several strengths. By utilizing data from over 25 million individuals across five countries and diverse healthcare settings, we have enabled a comprehensive investigation into the short-, medium-, and long-term psychiatric and neuropsychiatric sequelae of COVID-19. These enhance the precision, representativeness, and generalizability of our findings. To minimize potential confounding, we incorporated a significant amount of covariates into a large-scale regularized regression for covariate selection and propensity score calculation. Furthermore, using the OMOP CDM allowed us to standardize the study design, outcome definition, and analytical syntax within participating data partners. This standardization streamlined the process of generating and sharing results without disclosing individual-level data. It is important to note that our intention is not to compare the incidence or risks among different populations and healthcare systems, as database-specific properties are not comparable. Additionally, we have made the study package publicly available to encourage the reproduction of our findings&#160;and to foster collaboration.</p><p id="Par37">This study has limitations. First, phenotype ascertainment may be affected by the inherent measurement issues within our real-world databases. Although we used standardized diagnostic codes to identify outcomes, heterogeneity in diagnostic accuracy and coding processes across different healthcare settings persisted. Moreover, the specific diagnostic codes within the original data sources have not been validated, and their sensitivity and specificity require further exploration [<xref ref-type="bibr" rid="CR53">53</xref>]. Second, electronic medical record databases from four European countries (France, Italy, Germany, and the UK) were collected from primary care settings, which means inpatient records were not available for this study. Consequently, we could not capture outcomes diagnosed during hospital admissions. Third, several factors associated with the sequelae of COVID-19, such as infection severity, vaccination, and mortality, were not available in our databases, preventing detailed investigations into the effects of these factors on COVID-19 sequelae. Fourth, individuals in the comparator group might have had undiagnosed COVID-19 infection. To minimize the misclassification effect, we included all individuals with a COVID-19 diagnosis in healthcare institutions and positive SARS-CoV-2 screening test results from lab tests and adjusted the coding list for COVID-19 individuals&#8217; ascertainment during the data testing process. Fifth, we only considered incident psychiatric and neuropsychiatric diagnoses. Individuals who sought help repeatedly (with prolonged and more severe symptoms) were excluded from the mid- and long-term analysis, potentially resulting in an underestimation of the results. Sixth, our study only included unvaccinated individuals infected with COVID-19 in 2020, most of whom likely had no prior infection. Caution is warranted when generalizing our findings to other populations, as clinical consequences may differ between primary infections, reinfections, and breakthrough infections. Seventh, due to dataset limitations, we were only able to use a 1-year look-back period to exclude prevalent cases. As a result, some included individuals may not be &#8220;true&#8221; incident cases. Eighth, this study aimed to provide an overview of the association between psychiatric and neuropsychiatric disorders and COVID-19 across multiple databases, grouping outcomes of interest into 11 relatively broad disease categories. This approach was intended to ensure sufficient statistical power in each database and to simply reporting. However, it is possible that specific conditions within a category may have distinct associations with COVID-19, warranting future investigations. Finally, as with other observational studies, residual confounding was likely present in our study. For instance, individuals without COVID-19 infection were less likely than those with COVID-19 to present at healthcare institutions during the pandemic, reducing the probability of receiving diagnoses for other conditions and potentially overestimating our results.</p></sec><sec id="Sec10"><title>Conclusions</title><p id="Par38">In this multinational network cohort study examining the short- (6&#160;months), medium- (6&#160;months to 1&#160;year), and long-term (1 to 2&#160;years) psychiatric and neuropsychiatric sequelae of COVID-19, we consistently observed short-term risks of these conditions associated with COVID-19 across different countries. Notably, there were very few differences in these risks between individuals with and without COVID-19 infection after 6&#160;months. This phenomenon may be attributed to detection bias, the redirection of healthcare resources, diverse pandemic management strategies, and differing rates of socioeconomic recovery rather than the direct impact of COVID-19 itself. These findings underscore the complexity of the pandemic&#8217;s indirect effects on mental health. Further research is essential to elucidate the underlying causes of the medium- and long-term elevated risks of psychiatric and neuropsychiatric outcomes observed in France and the UK. Understanding these factors is crucial for developing targeted interventions and healthcare policies to mitigate these long-lasting impacts.</p></sec><sec id="Sec11" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12916_2025_3952_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Additional file 1: Fig. S1. Study cohort selection procedure, using short-term depression risk in France IQVIA as an example. Table S1. Descriptions of databases. Table S2. Diagnostic codes for COVID-19 identification. Table S3. Diagnostic codes for outcomes identification. Table S4. Sample size, sex and age distribution, follow-up time, the number of psychiatric and neuropsychiatric events, and incidence rate in the medium-term observation period by outcome and database. Table S5. Sample size, sex and age distribution, follow-up time, the number of psychiatric and neuropsychiatric events, and incidence rate in the long-term observation period by outcome and database. Table S6. Selected baseline characteristics for all outcomes in all databases. Table S7. Risk of developing outcome events among individuals with COVID-19 for the whole study sample. Table S8. Risk of developing outcome events among individuals with COVID-19 for males. Table S9. Risk of developing outcome events among individuals with COVID-19 for females. Table S10. Risk of developing outcome events among individuals with COVID-19 for individuals aged below 18 years. Table S11. Risk of developing outcome events among individuals with COVID-19 for individuals aged between 18 and 24 years. Table S12. Risk of developing outcome events among individuals with COVID-19 for individuals aged between 25 and 44 years. Table S13. Risk of developing outcome events among individuals with COVID-19 for individuals aged between 45 and 64 years. Table S14. Risk of developing outcome events among individuals with COVID-19 for individuals aged between 65 years or older.</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>France IQVIA</term><def><p id="Par5">IQVIA Longitudinal Patient Database France</p></def></def-item><def-item><term>Germany IQVIA</term><def><p id="Par6">IQVIA Disease Analyser Germany</p></def></def-item><def-item><term>Italy IQVIA</term><def><p id="Par7">Longitudinal Patient Database Italy</p></def></def-item><def-item><term>UK IMRD</term><def><p id="Par8">IQVIA Medical Research Data UK</p></def></def-item><def-item><term>US PharMetrics Plus</term><def><p id="Par9">IQVIA PharMetrics Plus in the USA</p></def></def-item><def-item><term>OMOP CDM</term><def><p id="Par10">Observational Medical Outcomes Partnership Common Data Model</p></def></def-item><def-item><term>OHDSI</term><def><p id="Par11">Observational Health Data Sciences and Informatics</p></def></def-item><def-item><term>HRs</term><def><p id="Par12">Hazard Ratios</p></def></def-item><def-item><term>CIs</term><def><p id="Par13">Confidence Intervals</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Yi Chai and Ivan C. H. Lam are co-first authors.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>Yi Chai, Ivan C.H. Lam, and Hao Luo contributed to the concept and design of the study. Yi Chai, Ivan C.H. Lam, Xiaoyu Lin, and Can Yin performed data analyses. Ian C.K. Wong obtained the funding. Yi Chai, Ivan C.H. Lam, Kenneth K.C. Man, Joseph F. Hayes, Eric Y.F. Wan, Xue Li, Celine S.L. Chui, Wallis C. Y. Lau, Xiaoyu Lin, Can Yin, Min Fan, Esther W. Chan, Ian C.K. Wong, and Hao Luo provided clinical, statistical, and epidemiological advice and interpreted the results. Yi Chai, Ivan C.H. Lam, and Hao Luo wrote and revised the first draft. All authors revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.</p><sec id="FPar1"><title>Authors&#8217; Twitter handles</title><p id="Par39">Twitter handles: @Yi_Chai18 (Yi Chai); @IVANCHLAM (Ivan C.H. Lam); @HaoLuo429 (Hao Luo); @Ian_HKU (Ian C.K. Wong).</p></sec></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by the Collaborative Research Fund, University Grants Committee, HKSAR Government (C7154-20GF).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Data are not available as the data custodians have not permitted data sharing due to patient confidentiality and privacy concerns.</p></notes><notes><title>Declarations</title><notes id="FPar2"><title>Ethics approval and consent to participate</title><p id="Par40">The data partners have obtained institutional review board exemption for their participation in this study. Informed consent was waived because the study used deidentified data, and no patients were contacted.</p></notes><notes id="FPar3"><title>Consent for publication</title><p id="Par41">Not applicable.</p></notes><notes id="FPar4" notes-type="COI-statement"><title>Competing interests</title><p id="Par42">Kenneth K.C. Man reports grants from the CW Maplethorpe Fellowship, National Institute of Health Research, UK, Hong Kong Research Grant Council and the European Commission Horizon 2020 Framework, personal fees from IQVIA and grants from Amgen and GlaxoSmithKline, outside the submitted work; Joseph F. Hayes reports grants from UKRI, NIHR UCLH Biomedical Research Centre, and Wellcome Trust and Consultancy Fees from Wellcome Trust and juli Health, outside the submitted work; Xue Li reports grants from the Hong Kong Health and Medical Research Fund (HMRF, HMRF Fellowship Scheme, HKSAR), Research Grants Council Early Career Scheme (RGC/ECS, HKSAR), Janssen, and Pfizer, internal funding from the University of Hong Kong; and consultancy fees from Merck Sharp &amp; Dohme and Pfizer, outside the submitted work; Eric Y.F. Wan reports grants from the Food and Health Bureau of the Government of the Hong Kong Special Administrative Region and the Hong Kong Research Grants Council, outside the submitted work; Celine S.L. Chui reports grants from the Food and Health Bureau of the Hong Kong Government, Hong Kong Research Grant Council, Hong Kong Innovation and Technology Commission, Pfizer, IQVIA, MSD, and Amgen and personal fees from PrimeVigilance, outside the submitted work; Wallis C.Y. Lau reports receiving grants from AIR@InnoHK administered by the Innovation and Technology Commission of Hong Kong, outside the submitted work; Esther W. Chan reports grants from Research Grants Council of Hong Kong, Research Fund Secretariat of the Food and Health Bureau of Hong Kong, National Natural Science Fund of China, Wellcome Trust, Bayer, Bristol-Myers Squibb, Pfizer, Janssen, Amgen, Takeda and Narcotics Division of the Security Bureau of Hong Kong; honorarium from Hospital Authority, outside the submitted work; Ian C.K. Wong reports grants from Amgen, Bristol-Myers Squibb, Pfizer, Janssen, Bayer, GSK and Novartis, the Hong Kong RGC, and the Hong Kong Health and Medical Research Fund in Hong Kong, National Institute for Health Research in England, European Commission, National Health and Medical Research Council in Australia, consulting fees from IQVIA, payment for expert testimony and is an independent non-executive director of Jacobson Medical in Hong Kong, outside of the submitted work; no other relationships or activities that could appear to have influenced the submitted work. Hao Luo reports grants from the Research Grants Council of Hong Kong, outside the submitted work; All other authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deer</surname><given-names>RR</given-names></name><name name-style="western"><surname>Rock</surname><given-names>MA</given-names></name><name name-style="western"><surname>Vasilevsky</surname><given-names>N</given-names></name><name name-style="western"><surname>Carmody</surname><given-names>L</given-names></name><name name-style="western"><surname>Rando</surname><given-names>H</given-names></name><name name-style="western"><surname>Anzalone</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Characterizing long COVID: deep phenotype of a complex condition</article-title><source>EBioMedicine</source><year>2021</year><volume>74</volume><fpage>103722</fpage><pub-id pub-id-type="pmid">34839263</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2021.103722</pub-id><pub-id pub-id-type="pmcid">PMC8613500</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Deer RR, Rock MA, Vasilevsky N, Carmody L, Rando H, Anzalone AJ, et al. Characterizing long COVID: deep phenotype of a complex condition. EBioMedicine. 2021;74:103722.<pub-id pub-id-type="pmid">34839263</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2021.103722</pub-id><pub-id pub-id-type="pmcid">PMC8613500</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsamakis</surname><given-names>K</given-names></name><name name-style="western"><surname>Tsiptsios</surname><given-names>D</given-names></name><name name-style="western"><surname>Ouranidis</surname><given-names>A</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>C</given-names></name><name name-style="western"><surname>Schizas</surname><given-names>D</given-names></name><name name-style="western"><surname>Terniotis</surname><given-names>C</given-names></name><etal/></person-group><article-title>COVID-19 and its consequences on mental health (Review)</article-title><source>Exp Ther Med</source><year>2021</year><volume>21</volume><issue>3</issue><fpage>244</fpage><pub-id pub-id-type="pmid">33603852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/etm.2021.9675</pub-id><pub-id pub-id-type="pmcid">PMC7851613</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Tsamakis K, Tsiptsios D, Ouranidis A, Mueller C, Schizas D, Terniotis C, et al. COVID-19 and its consequences on mental health (Review). Exp Ther Med. 2021;21(3):244.<pub-id pub-id-type="pmid">33603852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/etm.2021.9675</pub-id><pub-id pub-id-type="pmcid">PMC7851613</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schou</surname><given-names>TM</given-names></name><name name-style="western"><surname>Joca</surname><given-names>S</given-names></name><name name-style="western"><surname>Wegener</surname><given-names>G</given-names></name><name name-style="western"><surname>Bay-Richter</surname><given-names>C</given-names></name></person-group><article-title>Psychiatric and neuropsychiatric sequelae of COVID-19 &#8211; a systematic review</article-title><source>Brain Behav Immun</source><year>2021</year><volume>97</volume><fpage>328</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">34339806</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbi.2021.07.018</pub-id><pub-id pub-id-type="pmcid">PMC8363196</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Schou TM, Joca S, Wegener G, Bay-Richter C. Psychiatric and neuropsychiatric sequelae of COVID-19 &#8211; a systematic review. Brain Behav Immun. 2021;97:328&#8211;48.<pub-id pub-id-type="pmid">34339806</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbi.2021.07.018</pub-id><pub-id pub-id-type="pmcid">PMC8363196</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>E</given-names></name><name name-style="western"><surname>Al-Aly</surname><given-names>Z</given-names></name></person-group><article-title>Risks of mental health outcomes in people with covid-19: cohort study</article-title><source>BMJ</source><year>2022</year><volume>376</volume><fpage>e068993</fpage><pub-id pub-id-type="pmid">35172971</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj-2021-068993</pub-id><pub-id pub-id-type="pmcid">PMC8847881</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Xie Y, Xu E, Al-Aly Z. Risks of mental health outcomes in people with covid-19: cohort study. BMJ. 2022;376:e068993.<pub-id pub-id-type="pmid">35172971</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj-2021-068993</pub-id><pub-id pub-id-type="pmcid">PMC8847881</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><collab>The Lancet Psychiatry</collab></person-group><article-title>COVID-19 and mental health</article-title><source>Lancet Psychiatry</source><year>2021</year><volume>8</volume><issue>2</issue><fpage>87</fpage><pub-id pub-id-type="pmid">33485416</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2215-0366(21)00005-5</pub-id><pub-id pub-id-type="pmcid">PMC7825966</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">The Lancet Psychiatry. COVID-19 and mental health. Lancet Psychiatry. 2021;8(2):87.<pub-id pub-id-type="pmid">33485416</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2215-0366(21)00005-5</pub-id><pub-id pub-id-type="pmcid">PMC7825966</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boldrini</surname><given-names>M</given-names></name><name name-style="western"><surname>Canoll</surname><given-names>PD</given-names></name><name name-style="western"><surname>Klein</surname><given-names>RS</given-names></name></person-group><article-title>How COVID-19 affects the brain</article-title><source>JAMA Psychiat</source><year>2021</year><volume>78</volume><issue>6</issue><fpage>682</fpage><lpage>683</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapsychiatry.2021.0500</pub-id><pub-id pub-id-type="pmcid">PMC9894299</pub-id><pub-id pub-id-type="pmid">33769431</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Boldrini M, Canoll PD, Klein RS. How COVID-19 affects the brain. JAMA Psychiat. 2021;78(6):682&#8211;3.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapsychiatry.2021.0500</pub-id><pub-id pub-id-type="pmcid">PMC9894299</pub-id><pub-id pub-id-type="pmid">33769431</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Penninx</surname><given-names>B</given-names></name></person-group><article-title>Psychiatric symptoms and cognitive impairment in "Long COVID": the relevance of immunopsychiatry</article-title><source>World Psychiatry</source><year>2021</year><volume>20</volume><issue>3</issue><fpage>357</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">34505378</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/wps.20913</pub-id><pub-id pub-id-type="pmcid">PMC8429338</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Penninx B. Psychiatric symptoms and cognitive impairment in &#8220;Long COVID&#8221;: the relevance of immunopsychiatry. World Psychiatry. 2021;20(3):357&#8211;8.<pub-id pub-id-type="pmid">34505378</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/wps.20913</pub-id><pub-id pub-id-type="pmcid">PMC8429338</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rogers</surname><given-names>JP</given-names></name><name name-style="western"><surname>Chesney</surname><given-names>E</given-names></name><name name-style="western"><surname>Oliver</surname><given-names>D</given-names></name><name name-style="western"><surname>Pollak</surname><given-names>TA</given-names></name><name name-style="western"><surname>McGuire</surname><given-names>P</given-names></name><name name-style="western"><surname>Fusar-Poli</surname><given-names>P</given-names></name><etal/></person-group><article-title>Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic</article-title><source>Lancet Psychiatry</source><year>2020</year><volume>7</volume><issue>7</issue><fpage>611</fpage><lpage>627</lpage><pub-id pub-id-type="pmid">32437679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2215-0366(20)30203-0</pub-id><pub-id pub-id-type="pmcid">PMC7234781</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7(7):611&#8211;27.<pub-id pub-id-type="pmid">32437679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2215-0366(20)30203-0</pub-id><pub-id pub-id-type="pmcid">PMC7234781</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magn&#250;sd&#243;ttir</surname><given-names>I</given-names></name><name name-style="western"><surname>Lovik</surname><given-names>A</given-names></name><name name-style="western"><surname>Unnarsd&#243;ttir</surname><given-names>AB</given-names></name><name name-style="western"><surname>McCartney</surname><given-names>D</given-names></name><name name-style="western"><surname>Ask</surname><given-names>H</given-names></name><name name-style="western"><surname>K&#245;iv</surname><given-names>K</given-names></name><etal/></person-group><article-title>Acute COVID-19 severity and mental health morbidity trajectories in patient populations of six nations: an observational study</article-title><source>Lancet Public Health</source><year>2022</year><volume>7</volume><issue>5</issue><fpage>e406</fpage><lpage>e416</lpage><pub-id pub-id-type="pmid">35298894</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2468-2667(22)00042-1</pub-id><pub-id pub-id-type="pmcid">PMC8920517</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Magn&#250;sd&#243;ttir I, Lovik A, Unnarsd&#243;ttir AB, McCartney D, Ask H, K&#245;iv K, et al. Acute COVID-19 severity and mental health morbidity trajectories in patient populations of six nations: an observational study. Lancet Public Health. 2022;7(5):e406&#8211;16.<pub-id pub-id-type="pmid">35298894</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2468-2667(22)00042-1</pub-id><pub-id pub-id-type="pmcid">PMC8920517</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreno</surname><given-names>C</given-names></name><name name-style="western"><surname>Wykes</surname><given-names>T</given-names></name><name name-style="western"><surname>Galderisi</surname><given-names>S</given-names></name><name name-style="western"><surname>Nordentoft</surname><given-names>M</given-names></name><name name-style="western"><surname>Crossley</surname><given-names>N</given-names></name><name name-style="western"><surname>Jones</surname><given-names>N</given-names></name><etal/></person-group><article-title>How mental health care should change as a consequence of the COVID-19 pandemic</article-title><source>Lancet Psychiatry</source><year>2020</year><volume>7</volume><issue>9</issue><fpage>813</fpage><lpage>824</lpage><pub-id pub-id-type="pmid">32682460</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2215-0366(20)30307-2</pub-id><pub-id pub-id-type="pmcid">PMC7365642</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Moreno C, Wykes T, Galderisi S, Nordentoft M, Crossley N, Jones N, et al. How mental health care should change as a consequence of the COVID-19 pandemic. Lancet Psychiatry. 2020;7(9):813&#8211;24.<pub-id pub-id-type="pmid">32682460</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2215-0366(20)30307-2</pub-id><pub-id pub-id-type="pmcid">PMC7365642</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kola</surname><given-names>L</given-names></name><name name-style="western"><surname>Kohrt</surname><given-names>BA</given-names></name><name name-style="western"><surname>Hanlon</surname><given-names>C</given-names></name><name name-style="western"><surname>Naslund</surname><given-names>JA</given-names></name><name name-style="western"><surname>Sikander</surname><given-names>S</given-names></name><name name-style="western"><surname>Balaji</surname><given-names>M</given-names></name><etal/></person-group><article-title>COVID-19 mental health impact and responses in low-income and middle-income countries: reimagining global mental health</article-title><source>Lancet Psychiatry</source><year>2021</year><volume>8</volume><issue>6</issue><fpage>535</fpage><lpage>550</lpage><pub-id pub-id-type="pmid">33639109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2215-0366(21)00025-0</pub-id><pub-id pub-id-type="pmcid">PMC9764935</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Kola L, Kohrt BA, Hanlon C, Naslund JA, Sikander S, Balaji M, et al. COVID-19 mental health impact and responses in low-income and middle-income countries: reimagining global mental health. Lancet Psychiatry. 2021;8(6):535&#8211;50.<pub-id pub-id-type="pmid">33639109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2215-0366(21)00025-0</pub-id><pub-id pub-id-type="pmcid">PMC9764935</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taquet</surname><given-names>M</given-names></name><name name-style="western"><surname>Luciano</surname><given-names>S</given-names></name><name name-style="western"><surname>Geddes</surname><given-names>JR</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>PJ</given-names></name></person-group><article-title>Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62354 COVID-19 cases in the USA</article-title><source>Lancet Psychiatry</source><year>2021</year><volume>8</volume><issue>2</issue><fpage>130</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">33181098</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2215-0366(20)30462-4</pub-id><pub-id pub-id-type="pmcid">PMC7820108</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62354 COVID-19 cases in the USA. Lancet Psychiatry. 2021;8(2):130&#8211;40.<pub-id pub-id-type="pmid">33181098</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2215-0366(20)30462-4</pub-id><pub-id pub-id-type="pmcid">PMC7820108</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taquet</surname><given-names>M</given-names></name><name name-style="western"><surname>Geddes</surname><given-names>JR</given-names></name><name name-style="western"><surname>Husain</surname><given-names>M</given-names></name><name name-style="western"><surname>Luciano</surname><given-names>S</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>PJ</given-names></name></person-group><article-title>6-month neurological and psychiatric outcomes in 236379 survivors of COVID-19: a retrospective cohort study using electronic health records</article-title><source>Lancet Psychiatry</source><year>2021</year><volume>8</volume><issue>5</issue><fpage>416</fpage><lpage>427</lpage><pub-id pub-id-type="pmid">33836148</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2215-0366(21)00084-5</pub-id><pub-id pub-id-type="pmcid">PMC8023694</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8(5):416&#8211;27.<pub-id pub-id-type="pmid">33836148</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2215-0366(21)00084-5</pub-id><pub-id pub-id-type="pmcid">PMC8023694</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Su</surname><given-names>B</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J</given-names></name><name name-style="western"><surname>Garcia-Rizo</surname><given-names>C</given-names></name><name name-style="western"><surname>Prieto-Alhambra</surname><given-names>D</given-names></name></person-group><article-title>Long-term risk of psychiatric disorder and psychotropic prescription after SARS-CoV-2 infection among UK general population</article-title><source>Nat Hum Behav.</source><year>2024</year><volume>8</volume><issue>6</issue><fpage>1076</fpage><lpage>1087</lpage><pub-id pub-id-type="pmid">38514769</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41562-024-01853-4</pub-id><pub-id pub-id-type="pmcid">PMC11199144</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Wang Y, Su B, Xie J, Garcia-Rizo C, Prieto-Alhambra D. Long-term risk of psychiatric disorder and psychotropic prescription after SARS-CoV-2 infection among UK general population. Nat Hum Behav. 2024;8(6):1076&#8211;87.<pub-id pub-id-type="pmid">38514769</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41562-024-01853-4</pub-id><pub-id pub-id-type="pmcid">PMC11199144</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taquet</surname><given-names>M</given-names></name><name name-style="western"><surname>Sillett</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Mendel</surname><given-names>J</given-names></name><name name-style="western"><surname>Camplisson</surname><given-names>I</given-names></name><name name-style="western"><surname>Dercon</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1284437 patients</article-title><source>Lancet Psychiatry</source><year>2022</year><volume>9</volume><issue>10</issue><fpage>815</fpage><lpage>827</lpage><pub-id pub-id-type="pmid">35987197</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2215-0366(22)00260-7</pub-id><pub-id pub-id-type="pmcid">PMC9385200</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Taquet M, Sillett R, Zhu L, Mendel J, Camplisson I, Dercon Q, et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1284437 patients. Lancet Psychiatry. 2022;9(10):815&#8211;27.<pub-id pub-id-type="pmid">35987197</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2215-0366(22)00260-7</pub-id><pub-id pub-id-type="pmcid">PMC9385200</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lam</surname><given-names>ICH</given-names></name><name name-style="western"><surname>Wong</surname><given-names>CKH</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><name name-style="western"><surname>Chui</surname><given-names>CSL</given-names></name><name name-style="western"><surname>Lai</surname><given-names>FTT</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>Long-term post-acute sequelae of COVID-19 infection: a retrospective, multi-database cohort study in Hong Kong and the UK</article-title><source>EClinicalMedicine</source><year>2023</year><volume>60</volume><fpage>102000</fpage><pub-id pub-id-type="pmid">37197226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2023.102000</pub-id><pub-id pub-id-type="pmcid">PMC10173760</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Lam ICH, Wong CKH, Zhang R, Chui CSL, Lai FTT, Li X, et al. Long-term post-acute sequelae of COVID-19 infection: a retrospective, multi-database cohort study in Hong Kong and the UK. EClinicalMedicine. 2023;60:102000.<pub-id pub-id-type="pmid">37197226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2023.102000</pub-id><pub-id pub-id-type="pmcid">PMC10173760</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Penninx</surname><given-names>BWJH</given-names></name><name name-style="western"><surname>Benros</surname><given-names>ME</given-names></name><name name-style="western"><surname>Klein</surname><given-names>RS</given-names></name><name name-style="western"><surname>Vinkers</surname><given-names>CH</given-names></name></person-group><article-title>How COVID-19 shaped mental health: from infection to pandemic effects</article-title><source>Nat Med</source><year>2022</year><volume>28</volume><issue>10</issue><fpage>2027</fpage><lpage>2037</lpage><pub-id pub-id-type="pmid">36192553</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-022-02028-2</pub-id><pub-id pub-id-type="pmcid">PMC9711928</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Penninx BWJH, Benros ME, Klein RS, Vinkers CH. How COVID-19 shaped mental health: from infection to pandemic effects. Nat Med. 2022;28(10):2027&#8211;37.<pub-id pub-id-type="pmid">36192553</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-022-02028-2</pub-id><pub-id pub-id-type="pmcid">PMC9711928</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hripcsak</surname><given-names>G</given-names></name><name name-style="western"><surname>Duke</surname><given-names>JD</given-names></name><name name-style="western"><surname>Shah</surname><given-names>NH</given-names></name><name name-style="western"><surname>Reich</surname><given-names>CG</given-names></name><name name-style="western"><surname>Huser</surname><given-names>V</given-names></name><name name-style="western"><surname>Schuemie</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers</article-title><source>Stud Health Technol Inform</source><year>2015</year><volume>216</volume><fpage>574</fpage><lpage>578</lpage><pub-id pub-id-type="pmid">26262116</pub-id><pub-id pub-id-type="pmcid">PMC4815923</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#8211;8.<pub-id pub-id-type="pmid">26262116</pub-id><pub-id pub-id-type="pmcid">PMC4815923</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Ostropolets</surname><given-names>A</given-names></name><name name-style="western"><surname>Makadia</surname><given-names>R</given-names></name><name name-style="western"><surname>Shoaibi</surname><given-names>A</given-names></name><name name-style="western"><surname>Rao</surname><given-names>G</given-names></name><name name-style="western"><surname>Sena</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study</article-title><source>BMJ</source><year>2021</year><volume>373</volume><fpage>n1435</fpage><pub-id pub-id-type="pmid">35727911</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.n1435</pub-id><pub-id pub-id-type="pmcid">PMC8193077</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Li X, Ostropolets A, Makadia R, Shoaibi A, Rao G, Sena AG, et al. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. BMJ. 2021;373:n1435.<pub-id pub-id-type="pmid">35727911</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.n1435</pub-id><pub-id pub-id-type="pmcid">PMC8193077</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>H</given-names></name><name name-style="western"><surname>Lau</surname><given-names>WCY</given-names></name><name name-style="western"><surname>Chai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Torre</surname><given-names>CO</given-names></name><name name-style="western"><surname>Howard</surname><given-names>R</given-names></name><name name-style="western"><surname>Liu</surname><given-names>KY</given-names></name><etal/></person-group><article-title>Rates of antipsychotic drug prescribing among people living with dementia during the COVID-19 pandemic</article-title><source>JAMA Psychiat</source><year>2023</year><volume>80</volume><issue>3</issue><fpage>211</fpage><lpage>219</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapsychiatry.2022.4448</pub-id><pub-id pub-id-type="pmcid">PMC9878427</pub-id><pub-id pub-id-type="pmid">36696128</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Luo H, Lau WCY, Chai Y, Torre CO, Howard R, Liu KY, et al. Rates of antipsychotic drug prescribing among people living with dementia during the COVID-19 pandemic. JAMA Psychiat. 2023;80(3):211&#8211;9.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapsychiatry.2022.4448</pub-id><pub-id pub-id-type="pmcid">PMC9878427</pub-id><pub-id pub-id-type="pmid">36696128</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Man</surname><given-names>KKC</given-names></name><name name-style="western"><surname>Luo</surname><given-names>H</given-names></name><name name-style="western"><surname>Torre</surname><given-names>CO</given-names></name><name name-style="western"><surname>Wing</surname><given-names>YK</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Incidence of mental health diagnoses during the COVID-19 pandemic: a multinational network study</article-title><source>Epidemiol Psychiatr Sci</source><year>2024</year><volume>33</volume><fpage>e9</fpage><pub-id pub-id-type="pmid">38433286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S2045796024000088</pub-id><pub-id pub-id-type="pmcid">PMC10940053</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Chai Y, Man KKC, Luo H, Torre CO, Wing YK, Hayes JF, et al. Incidence of mental health diagnoses during the COVID-19 pandemic: a multinational network study. Epidemiol Psychiatr Sci. 2024;33:e9.<pub-id pub-id-type="pmid">38433286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S2045796024000088</pub-id><pub-id pub-id-type="pmcid">PMC10940053</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>H</given-names></name><name name-style="western"><surname>Chai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Lau</surname><given-names>WCY</given-names></name><name name-style="western"><surname>Torre</surname><given-names>CO</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>J</given-names></name><etal/></person-group><article-title>Psychotropic drug prescribing before and during the COVID-19 pandemic among people with depressive and anxiety disorders: a multinational network study</article-title><source>Lancet Psychiatry</source><year>2024</year><volume>11</volume><issue>10</issue><fpage>807</fpage><lpage>817</lpage><pub-id pub-id-type="pmid">39241791</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2215-0366(24)00245-1</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Luo H, Chai Y, Li S, Lau WCY, Torre CO, Hayes J, et al. Psychotropic drug prescribing before and during the COVID-19 pandemic among people with depressive and anxiety disorders: a multinational network study. Lancet Psychiatry. 2024;11(10):807&#8211;17.<pub-id pub-id-type="pmid">39241791</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2215-0366(24)00245-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Austin</surname><given-names>PC</given-names></name></person-group><article-title>Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies</article-title><source>Pharm Stat</source><year>2011</year><volume>10</volume><issue>2</issue><fpage>150</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">20925139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pst.433</pub-id><pub-id pub-id-type="pmcid">PMC3120982</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2):150&#8211;61.<pub-id pub-id-type="pmid">20925139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pst.433</pub-id><pub-id pub-id-type="pmcid">PMC3120982</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>Y</given-names></name><name name-style="western"><surname>Schuemie</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Suchard</surname><given-names>MA</given-names></name></person-group><article-title>Evaluating large-scale propensity score performance through real-world and synthetic data experiments</article-title><source>Int J Epidemiol</source><year>2018</year><volume>47</volume><issue>6</issue><fpage>2005</fpage><lpage>2014</lpage><pub-id pub-id-type="pmid">29939268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/dyy120</pub-id><pub-id pub-id-type="pmcid">PMC6280944</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Tian Y, Schuemie MJ, Suchard MA. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int J Epidemiol. 2018;47(6):2005&#8211;14.<pub-id pub-id-type="pmid">29939268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/dyy120</pub-id><pub-id pub-id-type="pmcid">PMC6280944</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lau</surname><given-names>WCY</given-names></name><name name-style="western"><surname>Torre</surname><given-names>CO</given-names></name><name name-style="western"><surname>Man</surname><given-names>KKC</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>HM</given-names></name><name name-style="western"><surname>Seager</surname><given-names>S</given-names></name><name name-style="western"><surname>Van Zandt</surname><given-names>M</given-names></name><etal/></person-group><article-title>Comparative effectiveness and safety between apixaban, dabigatran, edoxaban, and rivaroxaban among patients with atrial fibrillation : a multinational population-based cohort study</article-title><source>Ann Intern Med</source><year>2022</year><volume>175</volume><issue>11</issue><fpage>1515</fpage><lpage>1524</lpage><pub-id pub-id-type="pmid">36315950</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M22-0511</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Lau WCY, Torre CO, Man KKC, Stewart HM, Seager S, Van Zandt M, et al. Comparative effectiveness and safety between apixaban, dabigatran, edoxaban, and rivaroxaban among patients with atrial fibrillation&#8239;: a multinational population-based cohort study. Ann Intern Med. 2022;175(11):1515&#8211;24.<pub-id pub-id-type="pmid">36315950</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M22-0511</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suchard</surname><given-names>MA</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>SE</given-names></name><name name-style="western"><surname>Zorych</surname><given-names>I</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>P</given-names></name><name name-style="western"><surname>Madigan</surname><given-names>D</given-names></name></person-group><article-title>Massive parallelization of serial inference algorithms for a complex generalized linear model</article-title><source>ACM Trans Model Comput Simul.</source><year>2013</year><volume>23</volume><issue>1</issue><fpage>10</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1145/2414416.2414791</pub-id><pub-id pub-id-type="pmcid">PMC4201181</pub-id><pub-id pub-id-type="pmid">25328363</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Suchard MA, Simpson SE, Zorych I, Ryan P, Madigan D. Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Trans Model Comput Simul. 2013;23(1):10.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1145/2414416.2414791</pub-id><pub-id pub-id-type="pmcid">PMC4201181</pub-id><pub-id pub-id-type="pmid">25328363</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suchard</surname><given-names>MA</given-names></name><name name-style="western"><surname>Schuemie</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Krumholz</surname><given-names>HM</given-names></name><name name-style="western"><surname>You</surname><given-names>SC</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R</given-names></name><name name-style="western"><surname>Pratt</surname><given-names>N</given-names></name><etal/></person-group><article-title>Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis</article-title><source>Lancet</source><year>2019</year><volume>394</volume><issue>10211</issue><fpage>1816</fpage><lpage>1826</lpage><pub-id pub-id-type="pmid">31668726</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(19)32317-7</pub-id><pub-id pub-id-type="pmcid">PMC6924620</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019;394(10211):1816&#8211;26.<pub-id pub-id-type="pmid">31668726</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(19)32317-7</pub-id><pub-id pub-id-type="pmcid">PMC6924620</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hripcsak</surname><given-names>G</given-names></name><name name-style="western"><surname>Suchard</surname><given-names>MA</given-names></name><name name-style="western"><surname>Shea</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R</given-names></name><name name-style="western"><surname>You</surname><given-names>SC</given-names></name><name name-style="western"><surname>Pratt</surname><given-names>N</given-names></name><etal/></person-group><article-title>Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension</article-title><source>JAMA Intern Med</source><year>2020</year><volume>180</volume><issue>4</issue><fpage>542</fpage><lpage>551</lpage><pub-id pub-id-type="pmid">32065600</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamainternmed.2019.7454</pub-id><pub-id pub-id-type="pmcid">PMC7042845</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Hripcsak G, Suchard MA, Shea S, Chen R, You SC, Pratt N, et al. Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension. JAMA Intern Med. 2020;180(4):542&#8211;51.<pub-id pub-id-type="pmid">32065600</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamainternmed.2019.7454</pub-id><pub-id pub-id-type="pmcid">PMC7042845</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perlis</surname><given-names>RH</given-names></name><name name-style="western"><surname>Santillana</surname><given-names>M</given-names></name><name name-style="western"><surname>Ognyanova</surname><given-names>K</given-names></name><name name-style="western"><surname>Safarpour</surname><given-names>A</given-names></name><name name-style="western"><surname>Lunz Trujillo</surname><given-names>K</given-names></name><name name-style="western"><surname>Simonson</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Prevalence and correlates of long COVID symptoms among US adults</article-title><source>JAMA Netw Open.</source><year>2022</year><volume>5</volume><issue>10</issue><fpage>e2238804</fpage><lpage>e</lpage><pub-id pub-id-type="pmid">36301542</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2022.38804</pub-id><pub-id pub-id-type="pmcid">PMC9614581</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Perlis RH, Santillana M, Ognyanova K, Safarpour A, Lunz Trujillo K, Simonson MD, et al. Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw Open. 2022;5(10):e2238804-e.<pub-id pub-id-type="pmid">36301542</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2022.38804</pub-id><pub-id pub-id-type="pmcid">PMC9614581</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subramanian</surname><given-names>A</given-names></name><name name-style="western"><surname>Nirantharakumar</surname><given-names>K</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>S</given-names></name><name name-style="western"><surname>Myles</surname><given-names>P</given-names></name><name name-style="western"><surname>Williams</surname><given-names>T</given-names></name><name name-style="western"><surname>Gokhale</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Symptoms and risk factors for long COVID in non-hospitalized adults</article-title><source>Nat Med</source><year>2022</year><volume>28</volume><issue>8</issue><fpage>1706</fpage><lpage>1714</lpage><pub-id pub-id-type="pmid">35879616</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-022-01909-w</pub-id><pub-id pub-id-type="pmcid">PMC9388369</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28(8):1706&#8211;14.<pub-id pub-id-type="pmid">35879616</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-022-01909-w</pub-id><pub-id pub-id-type="pmcid">PMC9388369</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria; 2024 [cited 2024 May 15]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.R-project.org/">https://www.R-project.org/</ext-link></mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Schuemie M, Suchard M, Ryan P. CohortMethod: New-User Cohort Method with Large Scale Propensity and Outcome Models [online]. 2024 [cited 2024 May 15]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://ohdsi.github.io/CohortMethod/">https://ohdsi.github.io/CohortMethod/</ext-link></mixed-citation></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schuemie</surname><given-names>M</given-names></name><name name-style="western"><surname>Reps</surname><given-names>J</given-names></name><name name-style="western"><surname>Black</surname><given-names>A</given-names></name><name name-style="western"><surname>Defalco</surname><given-names>F</given-names></name><name name-style="western"><surname>Evans</surname><given-names>L</given-names></name><name name-style="western"><surname>Fridgeirsson</surname><given-names>E</given-names></name><etal/></person-group><article-title>Health-Analytics Data to Evidence Suite (HADES): open-source software for observational research</article-title><source>Stud Health Technol Inform</source><year>2024</year><volume>310</volume><fpage>966</fpage><lpage>970</lpage><pub-id pub-id-type="pmid">38269952</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/SHTI231108</pub-id><pub-id pub-id-type="pmcid">PMC10868467</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Schuemie M, Reps J, Black A, Defalco F, Evans L, Fridgeirsson E, et al. Health-Analytics Data to Evidence Suite (HADES): open-source software for observational research. Stud Health Technol Inform. 2024;310:966&#8211;70.<pub-id pub-id-type="pmid">38269952</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/SHTI231108</pub-id><pub-id pub-id-type="pmcid">PMC10868467</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elm</surname><given-names>Ev</given-names></name><name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name><name name-style="western"><surname>Egger</surname><given-names>M</given-names></name><name name-style="western"><surname>Pocock</surname><given-names>SJ</given-names></name><name name-style="western"><surname>G&#248;tzsche</surname><given-names>PC</given-names></name><name name-style="western"><surname>Vandenbroucke</surname><given-names>JP</given-names></name></person-group><article-title>Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies</article-title><source>BMJ.</source><year>2007</year><volume>335</volume><issue>7624</issue><fpage>806</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17947786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.39335.541782.AD</pub-id><pub-id pub-id-type="pmcid">PMC2034723</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Elm Ev, Altman DG, Egger M, Pocock SJ, G&#248;tzsche PC, Vandenbroucke JP. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806&#8211;8.<pub-id pub-id-type="pmid">17947786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.39335.541782.AD</pub-id><pub-id pub-id-type="pmcid">PMC2034723</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Badenoch</surname><given-names>JB</given-names></name><name name-style="western"><surname>Rengasamy</surname><given-names>ER</given-names></name><name name-style="western"><surname>Watson</surname><given-names>C</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>K</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>S</given-names></name><name name-style="western"><surname>Sundaram</surname><given-names>RD</given-names></name><etal/></person-group><article-title>Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis</article-title><source>Brain Commun.</source><year>2022</year><volume>4</volume><issue>1</issue><fpage>fcab297</fpage><pub-id pub-id-type="pmid">35169700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcab297</pub-id><pub-id pub-id-type="pmcid">PMC8833580</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Badenoch JB, Rengasamy ER, Watson C, Jansen K, Chakraborty S, Sundaram RD, et al. Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis. Brain Commun. 2022;4(1):fcab297.<pub-id pub-id-type="pmid">35169700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcab297</pub-id><pub-id pub-id-type="pmcid">PMC8833580</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Groff</surname><given-names>D</given-names></name><name name-style="western"><surname>Sun</surname><given-names>A</given-names></name><name name-style="western"><surname>Ssentongo</surname><given-names>AE</given-names></name><name name-style="western"><surname>Ba</surname><given-names>DM</given-names></name><name name-style="western"><surname>Parsons</surname><given-names>N</given-names></name><name name-style="western"><surname>Poudel</surname><given-names>GR</given-names></name><etal/></person-group><article-title>Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review</article-title><source>JAMA Netw Open.</source><year>2021</year><volume>4</volume><issue>10</issue><fpage>e2128568</fpage><lpage>e</lpage><pub-id pub-id-type="pmid">34643720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2021.28568</pub-id><pub-id pub-id-type="pmcid">PMC8515212</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. 2021;4(10):e2128568-e.<pub-id pub-id-type="pmid">34643720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2021.28568</pub-id><pub-id pub-id-type="pmcid">PMC8515212</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nasserie</surname><given-names>T</given-names></name><name name-style="western"><surname>Hittle</surname><given-names>M</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>SN</given-names></name></person-group><article-title>Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review</article-title><source>JAMA Netw Open.</source><year>2021</year><volume>4</volume><issue>5</issue><fpage>e2111417</fpage><lpage>e</lpage><pub-id pub-id-type="pmid">34037731</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2021.11417</pub-id><pub-id pub-id-type="pmcid">PMC8155823</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw Open. 2021;4(5):e2111417-e.<pub-id pub-id-type="pmid">34037731</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2021.11417</pub-id><pub-id pub-id-type="pmcid">PMC8155823</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ed&#233;n</surname><given-names>A</given-names></name><name name-style="western"><surname>Grahn</surname><given-names>A</given-names></name><name name-style="western"><surname>Bremell</surname><given-names>D</given-names></name><name name-style="western"><surname>Aghvanyan</surname><given-names>A</given-names></name><name name-style="western"><surname>Bathala</surname><given-names>P</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>D</given-names></name><etal/></person-group><article-title>Viral antigen and inflammatory biomarkers in cerebrospinal fluid in patients with COVID-19 infection and neurologic symptoms compared with control participants without infection or neurologic symptoms</article-title><source>JAMA Netw Open</source><year>2022</year><volume>5</volume><issue>5</issue><fpage>e2213253</fpage><pub-id pub-id-type="pmid">35604688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2022.13253</pub-id><pub-id pub-id-type="pmcid">PMC9127556</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Ed&#233;n A, Grahn A, Bremell D, Aghvanyan A, Bathala P, Fuchs D, et al. Viral antigen and inflammatory biomarkers in cerebrospinal fluid in patients with COVID-19 infection and neurologic symptoms compared with control participants without infection or neurologic symptoms. JAMA Netw Open. 2022;5(5):e2213253.<pub-id pub-id-type="pmid">35604688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2022.13253</pub-id><pub-id pub-id-type="pmcid">PMC9127556</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jagst</surname><given-names>M</given-names></name><name name-style="western"><surname>Pottk&#228;mper</surname><given-names>L</given-names></name><name name-style="western"><surname>G&#246;mer</surname><given-names>A</given-names></name><name name-style="western"><surname>Pitarokoili</surname><given-names>K</given-names></name><name name-style="western"><surname>Steinmann</surname><given-names>E</given-names></name></person-group><article-title>Neuroinvasion and neurotropism of severe acute respiratory syndrome coronavirus 2 infection</article-title><source>Curr Opin Microbiol</source><year>2024</year><volume>79</volume><fpage>102474</fpage><pub-id pub-id-type="pmid">38615394</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mib.2024.102474</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Jagst M, Pottk&#228;mper L, G&#246;mer A, Pitarokoili K, Steinmann E. Neuroinvasion and neurotropism of severe acute respiratory syndrome coronavirus 2 infection. Curr Opin Microbiol. 2024;79:102474.<pub-id pub-id-type="pmid">38615394</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mib.2024.102474</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spudich</surname><given-names>S</given-names></name><name name-style="western"><surname>Nath</surname><given-names>A</given-names></name></person-group><article-title>Nervous system consequences of COVID-19</article-title><source>Science</source><year>2022</year><volume>375</volume><issue>6578</issue><fpage>267</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">35050660</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abm2052</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Spudich S, Nath A. Nervous system consequences of COVID-19. Science. 2022;375(6578):267&#8211;9.<pub-id pub-id-type="pmid">35050660</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abm2052</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L</given-names></name><name name-style="western"><surname>Que</surname><given-names>J</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>The impact of quarantine on mental health status among general population in China during the COVID-19 pandemic</article-title><source>Mol Psychiatry</source><year>2021</year><volume>26</volume><issue>9</issue><fpage>4813</fpage><lpage>4822</lpage><pub-id pub-id-type="pmid">33483692</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-021-01019-y</pub-id><pub-id pub-id-type="pmcid">PMC7821451</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Wang Y, Shi L, Que J, Lu Q, Liu L, Lu Z, et al. The impact of quarantine on mental health status among general population in China during the COVID-19 pandemic. Mol Psychiatry. 2021;26(9):4813&#8211;22.<pub-id pub-id-type="pmid">33483692</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-021-01019-y</pub-id><pub-id pub-id-type="pmcid">PMC7821451</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>R</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W</given-names></name></person-group><article-title>Mental disorders associated with COVID-19 related unemployment</article-title><source>Appl Res Qual Life</source><year>2022</year><volume>17</volume><issue>2</issue><fpage>949</fpage><lpage>970</lpage><pub-id pub-id-type="pmid">33968280</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11482-021-09950-6</pub-id><pub-id pub-id-type="pmcid">PMC8096626</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Yao R, Wu W. Mental disorders associated with COVID-19 related unemployment. Appl Res Qual Life. 2022;17(2):949&#8211;70.<pub-id pub-id-type="pmid">33968280</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11482-021-09950-6</pub-id><pub-id pub-id-type="pmcid">PMC8096626</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alimoradi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ohayon</surname><given-names>MM</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>MD</given-names></name><name name-style="western"><surname>Lin</surname><given-names>CY</given-names></name><name name-style="western"><surname>Pakpour</surname><given-names>AH</given-names></name></person-group><article-title>Fear of COVID-19 and its association with mental health-related factors: systematic review and meta-analysis</article-title><source>BJPsych Open</source><year>2022</year><volume>8</volume><issue>2</issue><fpage>e73</fpage><pub-id pub-id-type="pmid">35307051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1192/bjo.2022.26</pub-id><pub-id pub-id-type="pmcid">PMC8943231</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Alimoradi Z, Ohayon MM, Griffiths MD, Lin CY, Pakpour AH. Fear of COVID-19 and its association with mental health-related factors: systematic review and meta-analysis. BJPsych Open. 2022;8(2):e73.<pub-id pub-id-type="pmid">35307051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1192/bjo.2022.26</pub-id><pub-id pub-id-type="pmcid">PMC8943231</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keyes</surname><given-names>KM</given-names></name><name name-style="western"><surname>Pratt</surname><given-names>C</given-names></name><name name-style="western"><surname>Galea</surname><given-names>S</given-names></name><name name-style="western"><surname>McLaughlin</surname><given-names>KA</given-names></name><name name-style="western"><surname>Koenen</surname><given-names>KC</given-names></name><name name-style="western"><surname>Shear</surname><given-names>MK</given-names></name></person-group><article-title>The burden of loss: unexpected death of a loved one and psychiatric disorders across the life course in a national study</article-title><source>Am J Psychiatry</source><year>2014</year><volume>171</volume><issue>8</issue><fpage>864</fpage><lpage>871</lpage><pub-id pub-id-type="pmid">24832609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.ajp.2014.13081132</pub-id><pub-id pub-id-type="pmcid">PMC4119479</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Keyes KM, Pratt C, Galea S, McLaughlin KA, Koenen KC, Shear MK. The burden of loss: unexpected death of a loved one and psychiatric disorders across the life course in a national study. Am J Psychiatry. 2014;171(8):864&#8211;71.<pub-id pub-id-type="pmid">24832609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.ajp.2014.13081132</pub-id><pub-id pub-id-type="pmcid">PMC4119479</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindau</surname><given-names>ST</given-names></name><name name-style="western"><surname>Makelarski</surname><given-names>JA</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>K</given-names></name><name name-style="western"><surname>Doyle</surname><given-names>KE</given-names></name><name name-style="western"><surname>Haider</surname><given-names>S</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name><etal/></person-group><article-title>Change in health-related socioeconomic risk factors and mental health during the early phase of the COVID-19 pandemic: a national survey of U.S. women</article-title><source>J Womens Health.</source><year>2021</year><volume>30</volume><issue>4</issue><fpage>502</fpage><lpage>13</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/jwh.2020.8879</pub-id><pub-id pub-id-type="pmcid">PMC8064961</pub-id><pub-id pub-id-type="pmid">33818123</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Lindau ST, Makelarski JA, Boyd K, Doyle KE, Haider S, Kumar S, et al. Change in health-related socioeconomic risk factors and mental health during the early phase of the COVID-19 pandemic: a national survey of U.S. women. J Womens Health. 2021;30(4):502&#8211;13.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/jwh.2020.8879</pub-id><pub-id pub-id-type="pmcid">PMC8064961</pub-id><pub-id pub-id-type="pmid">33818123</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>X</given-names></name><name name-style="western"><surname>Guan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Dong</surname><given-names>J</given-names></name><etal/></person-group><article-title>Long-term sequelae of different COVID-19 variants: the original strain versus the Omicron variant</article-title><source>Glob Health Med</source><year>2022</year><volume>4</volume><issue>6</issue><fpage>322</fpage><lpage>326</lpage><pub-id pub-id-type="pmid">36589219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.35772/ghm.2022.01069</pub-id><pub-id pub-id-type="pmcid">PMC9773225</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Liao X, Guan Y, Liao Q, Ma Z, Zhang L, Dong J, et al. Long-term sequelae of different COVID-19 variants: the original strain versus the Omicron variant. Glob Health Med. 2022;4(6):322&#8211;6.<pub-id pub-id-type="pmid">36589219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.35772/ghm.2022.01069</pub-id><pub-id pub-id-type="pmcid">PMC9773225</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>M</given-names></name></person-group><article-title>COVID-19-related stigma and its impact on psychological distress: a cross-sectional study in Wuhan, China</article-title><source>Health Sci Rep</source><year>2022</year><volume>5</volume><issue>5</issue><fpage>e758</fpage><pub-id pub-id-type="pmid">35949673</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hsr2.758</pub-id><pub-id pub-id-type="pmcid">PMC9358535</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Zhou M. COVID-19-related stigma and its impact on psychological distress: a cross-sectional study in Wuhan, China. Health Sci Rep. 2022;5(5):e758.<pub-id pub-id-type="pmid">35949673</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hsr2.758</pub-id><pub-id pub-id-type="pmcid">PMC9358535</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scholz</surname><given-names>U</given-names></name><name name-style="western"><surname>Bierbauer</surname><given-names>W</given-names></name><name name-style="western"><surname>L&#252;scher</surname><given-names>J</given-names></name></person-group><article-title>Social stigma, mental health, stress, and health-related quality of life in people with long COVID</article-title><source>Int J Environ Res Public Health.</source><year>2023</year><volume>20</volume><issue>5</issue><fpage>3927</fpage><pub-id pub-id-type="pmid">36900938</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijerph20053927</pub-id><pub-id pub-id-type="pmcid">PMC10001775</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Scholz U, Bierbauer W, L&#252;scher J. Social stigma, mental health, stress, and health-related quality of life in people with long COVID. Int J Environ Res Public Health. 2023;20(5):3927.<pub-id pub-id-type="pmid">36900938</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijerph20053927</pub-id><pub-id pub-id-type="pmcid">PMC10001775</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lam</surname><given-names>ICH</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><name name-style="western"><surname>Man</surname><given-names>KKC</given-names></name><name name-style="western"><surname>Wong</surname><given-names>CKH</given-names></name><name name-style="western"><surname>Chui</surname><given-names>CSL</given-names></name><name name-style="western"><surname>Lai</surname><given-names>FTT</given-names></name><etal/></person-group><article-title>Persistence in risk and effect of COVID-19 vaccination on long-term health consequences after SARS-CoV-2 infection</article-title><source>Nat Commun</source><year>2024</year><volume>15</volume><issue>1</issue><fpage>1716</fpage><pub-id pub-id-type="pmid">38403654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-45953-1</pub-id><pub-id pub-id-type="pmcid">PMC10894867</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Lam ICH, Zhang R, Man KKC, Wong CKH, Chui CSL, Lai FTT, et al. Persistence in risk and effect of COVID-19 vaccination on long-term health consequences after SARS-CoV-2 infection. Nat Commun. 2024;15(1):1716.<pub-id pub-id-type="pmid">38403654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-45953-1</pub-id><pub-id pub-id-type="pmcid">PMC10894867</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Servier</surname><given-names>C</given-names></name><name name-style="western"><surname>Porcher</surname><given-names>R</given-names></name><name name-style="western"><surname>Pane</surname><given-names>I</given-names></name><name name-style="western"><surname>Ravaud</surname><given-names>P</given-names></name><name name-style="western"><surname>Tran</surname><given-names>V-T</given-names></name></person-group><article-title>Trajectories of the evolution of post-COVID-19 condition, up to two years after symptoms onset</article-title><source>Int J Infect Dis</source><year>2023</year><volume>133</volume><fpage>67</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">37182548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijid.2023.05.007</pub-id><pub-id pub-id-type="pmcid">PMC10176960</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Servier C, Porcher R, Pane I, Ravaud P, Tran V-T. Trajectories of the evolution of post-COVID-19 condition, up to two years after symptoms onset. Int J Infect Dis. 2023;133:67&#8211;74.<pub-id pub-id-type="pmid">37182548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijid.2023.05.007</pub-id><pub-id pub-id-type="pmcid">PMC10176960</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daly</surname><given-names>M</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>E</given-names></name></person-group><article-title>Psychological distress and adaptation to the COVID-19 crisis in the United States</article-title><source>J Psychiatr Res</source><year>2021</year><volume>136</volume><fpage>603</fpage><lpage>609</lpage><pub-id pub-id-type="pmid">33138985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpsychires.2020.10.035</pub-id><pub-id pub-id-type="pmcid">PMC7588823</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Daly M, Robinson E. Psychological distress and adaptation to the COVID-19 crisis in the United States. J Psychiatr Res. 2021;136:603&#8211;9.<pub-id pub-id-type="pmid">33138985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpsychires.2020.10.035</pub-id><pub-id pub-id-type="pmcid">PMC7588823</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tahara</surname><given-names>M</given-names></name><name name-style="western"><surname>Mashizume</surname><given-names>Y</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>K</given-names></name></person-group><article-title>Coping mechanisms: exploring strategies utilized by Japanese healthcare workers to reduce stress and improve mental health during the COVID-19 pandemic</article-title><source>Int J Environ Res Public Health.</source><year>2021</year><volume>18</volume><issue>1</issue><fpage>131</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijerph18010131</pub-id><pub-id pub-id-type="pmcid">PMC7795636</pub-id><pub-id pub-id-type="pmid">33375444</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Tahara M, Mashizume Y, Takahashi K. Coping mechanisms: exploring strategies utilized by Japanese healthcare workers to reduce stress and improve mental health during the COVID-19 pandemic. Int J Environ Res Public Health. 2021;18(1):131.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijerph18010131</pub-id><pub-id pub-id-type="pmcid">PMC7795636</pub-id><pub-id pub-id-type="pmid">33375444</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Burn</surname><given-names>E</given-names></name><name name-style="western"><surname>Duarte-Salles</surname><given-names>T</given-names></name><name name-style="western"><surname>Yin</surname><given-names>C</given-names></name><name name-style="western"><surname>Reich</surname><given-names>C</given-names></name><name name-style="western"><surname>Delmestri</surname><given-names>A</given-names></name><etal/></person-group><article-title>Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US</article-title><source>BMJ</source><year>2022</year><volume>379</volume><fpage>e071594</fpage><pub-id pub-id-type="pmid">36288813</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj-2022-071594</pub-id><pub-id pub-id-type="pmcid">PMC9597610</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Li X, Burn E, Duarte-Salles T, Yin C, Reich C, Delmestri A, et al. Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US. BMJ. 2022;379:e071594.<pub-id pub-id-type="pmid">36288813</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj-2022-071594</pub-id><pub-id pub-id-type="pmcid">PMC9597610</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>